10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(MARK ONE)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to __________

Commission file number: 001-33509

RESPONSE GENETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	11-3525548
(State or other jurisdiction of incorporation or	(I.R.S. Employer Identification No.)
organization)
1640 Marengo St., 6th Floor, Los Angeles, California	90033
(Address of principal executive offices)	(Zip Code)

(323) 224-3900

(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company x
(do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

On November 13, 2012, there were 32,797,625 shares of common stock, $.01 par value per share, issued and outstanding.

Response Genetics, Inc.

Form 10-Q

Table of Contents

		Page
		Number
Part I.	Financial Information
Item 1.	Financial Statements
	Consolidated Balance Sheets — December 31, 2011 and September 30, 2012 (Unaudited)	1
	Unaudited Consolidated Statements of Operations and Comprehensive Loss — Three and nine months ended September 30, 2011 and 2012	2
	Unaudited Consolidated Statements of Cash Flows —Nine months ended September 30, 2011 and 2012	3
	Notes to Unaudited Consolidated Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Qualitative and Quantitative Disclosures About Market Risk	32
Item 4.	Controls and Procedures	32
Part II.	Other Information
Item 1.	Legal Proceedings	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults Upon Senior Securities	33
Item 4.	Mine Safety Disclosures	33
Item 5.	Other Information	33
Item 6.	Exhibits	33
Signatures		34
Exhibit Index
	EX-31.1 (Certification required under Section 302 of the Sarbanes-Oxley Act of 2002)
	EX-31.2 (Certification required under Section 302 of the Sarbanes-Oxley Act of 2002)
	EX-32 (Certification required under Section 906 of the Sarbanes-Oxley Act of 2002)

ii

RESPONSE GENETICS, INC.

CONSOLIDATED BALANCE SHEETS

	December 31, 2011			September 30, 2012
				(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	1,700,295		$	10,839,201
Accounts receivable, net of allowance for doubtful accounts of $838,750 and $864,419 at December 31, 2011 and September 30, 2012, respectively.		4,047,059			4,383,958
Prepaid expenses and other current assets		991,351			447,494
Total current assets		6,738,705			15,670,653
Property and equipment, net		1,045,287			1,026,562
Intangible assets		66,815			464,010
Total assets	$	7,850,807		$	17,161,225
LIABILITIES, COMMON STOCK CLASSIFED OUTSIDE OF STOCKHOLDERS’ EQUITY (DEFICIT) AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accounts payable	$	1,492,526		$	1,348,241
Accrued expenses		1,149,741			412,390
Accrued royalties		738,832			692,631
Accrued payroll and related liabilities		1,362,689			1,029,017
Capital lease obligation, current portion		149,253			158,821
Line of credit		1,000,000			1,000,000
Deferred revenue		-			803,481
Total current liabilities		5,893,041			5,444,581
Capital lease obligation, net of current portion		240,928			122,021
Total liabilities		6,133,969			5,566,602
Commitments and contingencies (Note 5)
Common stock classified outside of stockholders’ equity (deficit)		7,854,682			19,575,724
Stockholders’ equity (deficit)
Common stock, $0.01 par value; 50,000,000 shares authorized; 19,540,358 and 32,797,625 shares issued and outstanding at December 31, 2011 and September 30, 2012, respectively		134,327			172,414
Additional paid-in capital		43,514,591			48,904,324
Accumulated deficit		(49,519,585	)		(56,789,324	)
Accumulated other comprehensive loss		(267,177	)		(268,515	)
Total stockholders’ equity (deficit)		(6,137,844	)		(7,981,101	)
Total liabilities, common stock classified outside of stockholders’ equity (deficit) and stockholders’ equity (deficit)	$	7,850,807		$	17,161,225

The accompanying notes are an integral part of these consolidated financial statements.

1

RESPONSE GENETICS, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Three Months Ended September 30,						Nine Months Ended September 30
	2011			2012			2011			2012
Net revenue	$	5,100,649		$	5,403,537		$	17,730,785		$	13,220,188
Operating expenses:
Cost of revenue		2,538,176			2,768,894			8,040,003			7,895,870
Selling and marketing		1,251,054			1,195,988			4,107,639			4,145,115
General and administrative		2,268,517			2,407,544			6,493,079			6,686,559
Research and development		452,734			426,105			838,622			1,695,851
Total operating expenses		6,510,481			6,798,531			19,479,343			20,423,395
Operating loss		(1,409,832	)		(1,394,994	)		(1,748,558	)		(7,203,207	)
Other income (expense):
Interest expense		(5,804	)		(20,497	)		(11,379	)		(66,556	)
Interest income		96			3			162			24
Net loss	$	(1,415,540	)	$	(1,415,488	)	$	(1,759,775	)	$	(7,269,739	)
Unrealized gain (loss) on foreign currency translation		(25,593	)		968			(25,593	)		(1,338	)
Total comprehensive loss	$	(1,441,133	)	$	(1,414,520	)	$	(1,785,368	)	$	(7,271,077	)
Net loss per share — basic and diluted	$	(0.07	)	$	(0.05	)	$	(0.09	)	$	(0.29	)
Weighted-average shares — basic and diluted		19,537,232			26,362,842			18,979,010			24,709,185

The accompanying notes are an integral part of these consolidated financial statements.

2

RESPONSE GENETICS, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months Ended September 30,
	2011			2012
Cash flows from operating activities:
Net loss	$	(1,759,775	)	$	(7,269,739	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		262,591			348,284
Share-based compensation		703,771			683,897
Bad debt expense		460,883			897,182
Loss on sale of property and equipment		7,728			—
Asset impairment		157,241			—
Changes in operating assets and liabilities:
Accounts receivable		(823,671	)		(1,211,800	)
Prepaid expenses and other current assets		148,244			520,632
Accounts payable		(46,697	)		(144,285	)
Accrued expenses		(787,047	)		(737,351	)
Accrued royalties		(331,803	)		(46,201	)
Accrued payroll and related liabilities		(174,863	)		(333,672	)
Deferred revenue		(1,133,316	)		803,481
Net cash used in operating activities		(3,316,714	)		(6,489,572	)
Cash flows from investing activities:
Purchases of property and equipment		(287,995	)		(312,477	)
Purchases and capitalization of software		(69,159	)		(414,277	)
Net cash used in investing activities		(357,154	)		(726,754	)
Cash flows from financing activities:
Net proceeds from issuance of common stock		2,179,535			16,464,965
Proceeds on exercise of stock options		5,411			—
Capital lease payments		(16,041	)		(109,339	)
Net cash provided by financing activities		2,168,905			16,355,626
Effect of foreign exchange rates on cash and cash equivalents		(83,102	)		(394	)
Net increase (decrease) in cash and cash equivalents		(1,588,065	)		9,138,906
Cash and cash equivalents:
Beginning of period		4,120,074			1,700,295
End of period	$	2,532,009		$	10,839,201
Cash paid during the period for:
Interest	$	11,379		$	66,556

The accompanying notes are an integral part of these consolidated financial statements.

3

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization, Operations and Basis of Accounting

Response Genetics, Inc. (the “Company”) is a life sciences company engaged in the pharmacogenomic research, development, marketing and sale of tests for use in the diagnosis and treatment of cancer. The Company was incorporated in the state of Delaware on September 23, 1999 as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Pharmacogenomics is the science of how an individual’s genetic makeup relates to drug response. Tests based on pharmacogenomics facilitate the prediction of a response to drug therapy or survival following surgery based on an individual’s genetic makeup. In order to generate information from patient specimens for these tests, the Company developed and patented methods for maximizing the extraction and analysis of nucleic acids and, therefore, accessing the genetic information available from each patient sample. The Company’s platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as global gene interrogation using microarray methods from paraffin or frozen tissue specimens. The Company continues to also expand its platforms utilizing multiple approaches thereby providing what the Company believes is better patient care. The Company primarily derives its revenue from the sale of its ResponseDX^® diagnostic testing products and by providing testing services to pharmaceutical companies in the United States, Asia and Europe.

The Company’s goal is to provide cancer patients and their physicians with a means to make informed, individualized treatment decisions based on genetic analysis of tumor tissues. The Company’s analysis of clinical trial specimens for the pharmaceutical industry may provide data that will lead to a better understanding of the molecular basis for response to specific drugs and, therefore lead to individualized treatment.

Since its inception, the Company has devoted substantial effort in developing its products and has incurred losses and negative cash flows from operations. At September 30, 2012, the Company had an accumulated deficit of $56,789,324. The Company anticipates continued losses and negative cash flows as it funds its selling and marketing activities and research and development programs.

The Company’s current operating plan includes various assumptions concerning the level and timing of cash receipts from product sales and cash outlays for operating expenses and capital expenditures.  The Company’s ability to successfully carry out its business plan is primarily dependent upon its ability to (1) obtain sufficient capital at acceptable costs, (2) attract and retain knowledgeable workers, and (3) generate significant revenues.

However, if events or circumstances occur such that the Company does not meet its operating plan as expected, in addition to seeking additional capital, the Company will most likely be required to reduce certain spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives.  No adjustments have been made to the accompanying financial statements to reflect any of the matters discussed above.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q promulgated by the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for interim periods are not necessarily indicative of the results that may be expected for the fiscal year. The financial statements should be read in conjunction with the Company’s audited December 31, 2010 and 2011 consolidated financial statements and accompanying notes included in the Company’s Form 10-K and 10-K/A previously filed with the SEC.

2. Summary of Significant Accounting Policies

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Response Genetics, Ltd., a Scottish corporation, which was incorporated in November 2006. All significant intercompany transactions and balances have been eliminated in consolidation.

Reclassification

Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company’s financial condition as of December 31, 2011 nor statement of operations for the period ended September 30, 2011.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity date of three months or less from the date of purchase to be cash equivalents. The carrying value of cash equivalents approximates fair value due to the short-term nature and liquidity of these instruments. The Company’s cash equivalents are comprised of cash on hand, deposits in banks and money market investments.

4

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

2. Summary of Significant Accounting Policies (continued)

Accounts Receivable

Pharmaceutical Accounts Receivable

The Company invoices its clients as specimens are processed and any other contractual obligations are met. The Company’s contracts with clients typically require payment within 45 days of the date of invoice. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its clients to make required payments. The Company specifically analyzes accounts receivable and historical bad debts, client credit, current economic trends and changes in client payment trends when evaluating the adequacy of the allowance for doubtful accounts. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered. To date, the Company’s pharmaceutical customers have primarily been large pharmaceutical companies. As a result, bad debts from pharmaceutical accounts receivable to date have been minimal. Pharmaceutical company accounts receivable as of December 31, 2011 and September 30, 2012 were $1,701,837 and $1,423,646, respectively.  There were no allowances for doubtful accounts recorded against these pharmaceutical accounts receivable at December 31, 2011 and September 30, 2012.

ResponseDX^® Accounts Receivable

ResponseDX^® accounts receivable are recorded from two primary payors: Medicare and third party and private payors (“Private Payors”).  ResponseDX^® accounts receivable are recorded at established billing rates less an estimated billing adjustment, based on reporting models utilizing historical cash collection percentages and updated for current effective reimbursement factors.  Management performs ongoing valuations of accounts receivable balances based on management’s evaluation of historical collection experience and industry trends in order to record an allowance for doubtful accounts.  Based on the historical experience for the Company’s Medicare and Private Payor accounts, management has determined that related accounts receivable associated with billings over one year are unlikely to be collected.  Any outstanding receivable balance that is over one year old is written off. The Company’s bad debt expense for the three months ended September 30, 2011 and 2012, was $160,952 and $589,917, respectively, and $460,883 and $897,128 for the nine months ended September 30, 2011 and 2012.

ResponseDX^® accounts receivable as of December 31, 2011 and September 30, 2012, consisted of the following:

	December 31, 2011			September 30, 2012
				(Unaudited)
Net Medicare receivable	$	506,308		$	774,237
Net Private Payor receivable		2,634,838			3,050,494
Other		42,826			—
		3,183,972			3,824,731
Allowance for doubtful accounts		(838,750	)		(864,419	)
Total	$	2,345,222		$	2,960,312

Property and Equipment

Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the double declining balance and straight-line methods over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows:

Laboratory equipment	5 to 7 years
Furniture and Equipment	5 to 7 years
Leasehold Improvements	Shorter of the useful life (5 to 7 years) or the lease term

Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. The Company has capitalized costs related to the development of database software (see Note 3). The portion of this database placed into service is amortized in accordance with ASC 350-40, Internal-Use Software. The amortization period is three years using the straight-line method.

5

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

2. Summary of Significant Accounting Policies - (continued)

Revenue Recognition

Pharmaceutical Revenue

Revenues that are derived from testing services provided to pharmaceutical companies are recognized on a contract specific basis pursuant to the terms of the related agreements. Revenue is recognized in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.

Revenues are recorded on an accrual basis as the contractual obligations are completed and as a set of assays is processed through the Company’s laboratory under a specified contractual protocol and are recorded on the date the tests are resulted. Certain contracts have minimum assay requirements that, if not met, result in payments that are due upon the completion of the designated period. In these cases, revenues are recognized when the end of the specified contract period is reached.

On occasion, the Company may enter into a contract that requires the client to provide an advance payment for specimens that will be processed at a later date. In these cases, the Company records this advance as deferred revenue and recognizes the revenue as the specimens are processed or at the end of the contract period, as appropriate.

ResponseDX^® Revenue

Revenues that are derived from ResponseDX^® testing services are recognized in accordance with ASC 605, Revenue Recognition , which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered.  (3) the price is fixed or determinable; and (4) collectability is reasonably assured. We record revenues when our tests have confirmed results which is evidence that the services have been performed.

Revenues are recorded on an accrual basis as the contractual obligations are completed and as a set of assays is processed through our laboratory under a specified contractual protocol.

ResponseDX^® Private Payor and Medicare revenues are recorded on an accrual basis at established billing rates less an estimated billing adjustment, based on reporting models utilizing historical cash collection percentages and updated for current effective reimbursement factors. The Company’s Medicare provider number allows it to invoice and collect from Medicare. The Company’s invoicing to Medicare is primarily based on amounts allowed by Medicare for the service provided as defined by Common Procedural Terminology (“CPT”).

The following details ResponseDX^® revenue for the three and nine months ended September 30, 2011 and 2012:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	(Unaudited)				(Unaudited)
	2011		2012		2011		2012
Net Medicare revenue	$	1,572,807	$	1,227,893	$	4,029,675	$	3,995,200
Private Payor revenue		1,765,753		1,795,723		5,389,199		4,814,403
Other		2,076		-		6,873		-
Net ResponseDX® revenue	$	3,340,636	$	3,023,616	$	9,425,747	$	8,809,603

6

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

2. Summary of Significant Accounting Policies - (continued)

Revenue Recognition – (continued)

Cost-Containment Measures

Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of health care services, which include diagnostic test providers such as the Company, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.

Regulatory Matters

A portion of the Company’s revenues are derived from Medicare reimbursement. Laws and regulations governing Medicare programs are complex and subject to interpretation, and the Company may be adversely affected by future governmental investigations, lawsuits or private actions which include mandatory damages, fines, penalties, criminal charges, loss of suspension of licenses and/or suspension or exclusion from Medicare and certain other governmental programs. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing.

Medicare reimbursement rates are subject to regulatory changes and government funding restrictions. The Company is aware of public comments and associated commentary related to future rate changes that may occur in early 2013. Significant changes to the reimbursement rates could have a material adverse effect on the Company’s operations.

Cost of Revenue

Cost of revenue represents the cost of materials, direct labor, royalties, costs associated with processing tissue specimens including pathological review, staining, microdissection, paraffin extraction, reverse transcription polymerase chain reaction, ALK Break Apart fluorescence in situ hybridization (FISH), quality control analyses, license fees and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.

License Fees

The Company has licensed technology for the extraction of mRNA from formalin-fixed, paraffin-embedded tumor specimens from the University of Southern California (“USC”). Under the terms of the license agreement, the Company is required to pay royalties to USC based on the revenue generated by use of this technology. The Company maintains a non-exclusive license to use certain patents related to the polymerase chain reaction (“PCR”) of Roche Molecular Systems, Inc. (“Roche”). The Company pays Roche a royalty fee based on revenue that the Company generates through use of this technology. The Company accrues for such royalties at the time revenue is recognized. Such royalties are included in cost of revenues in the accompanying statements of operations.

7

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

2. Summary of Significant Accounting Policies - (continued)

Research and Development

The Company expenses costs associated with research and development activities as incurred. Research and development costs are expensed as incurred in relation to direct costs that can be identified and classified as research and development costs. Certain costs such as lab supplies and reagents that cannot be specifically identified are allocated based on the number of samples processed in total by the lab and R&D departments in total. Research and development costs include employee costs (salaries, payroll taxes, benefits, and travel), equipment depreciation and warranties and maintenance, laboratory supplies, primers and probes, reagents, patent costs and occupancy costs.

Line of Credit

On July 14, 2011, the Company entered into a line of credit agreement with Silicon Valley Bank (the “Bank”). The agreement has been amended most recently on September 28, 2012. The line of credit is collateralized by the Company’s pharmaceutical and Medicare receivables. The amended maximum amount that can be borrowed from the credit line is $2,000,000. The amount the Company can draw from the loan is equal to the calculated borrowing base, which is 80% of the Company’s pharmaceutical accounts receivable that have not aged greater than 90 days. As of September 30, 2012, the amount available for the borrowing base is fixed at $1,500,000 until November 30, 2012. As part of the line of credit the Bank will issue letters of credit up to a maximum amount of $500,000. Any issued letters of credit reduce the amount available to borrow under the line of credit on a dollar for dollar basis. The interest fees associated with this line of credit are set at the prime rate plus 1%. For the period ended September 30, 2012, the rate being charged to the Company was 5%. As needed from time to time, the Company may draw on this line for use for general corporate purposes. As of December 31, 2011 and September 30, 2012, the Company has drawn $1,000,000 against the line of credit and no letters of credit were outstanding. The line of credit is subject to various financial covenants and, as of September 30, 2012, the Company was not in compliance with certain covenants. The September 28, 2012 amendment provided forbearance for the failure to comply with these certain covenants through November 30, 2012, and the amendment modified the covenants to include a requirement that the Company maintain account balances at the Bank totaling a minimum of $4,000,000 during the forbearance period. Management intends to utilize the forbearance period to restructure the line of credit agreement and any related covenant compliance issues. As of December 31, 2011, and September 30, 2012, the line of credit was classified as a current liability of the Company on the accompanying balance sheet. However, there can be no assurance that the Company will be able to restructure the line of credit agreement during the forbearance period on terms acceptable to the Company, or at all, nor can there be any assurance that the Company will be able to resolve all such covenant compliance issues during the forbearance period.

From time to time the Company’s borrowing base under its Bank line of credit may decrease to a level where the Company is in an over-advance position. This occurred on one occasion during the second quarter of 2012 based on the May 2012 borrowing base, as a result of which the Company was required to repay $298,000 to the Bank. The Company drew down the same amount one week later once the June 2012 borrowing base was determined to be sufficiently higher than the May 2012 borrowing base, thereby giving the Company the capacity to borrow such additional amount.

Income Taxes

Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

ASC 740, Income Taxes , clarifies the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of December 31, 2011 and September 30, 2012, the Company does not have a liability for unrecognized tax benefits. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related tax liability in the balance sheet. For the period ended September 30, 2012 there were no interest or penalties recorded on the Consolidated Statement of Operations.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Stock Compensation, Share-Based Payment. Stock-based compensation expense for all stock-based compensation awards granted is based on the grant-date fair value estimated in accordance with the provisions of ASC 718.  The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting period. As further described in Note 7, certain awards granted to Thomas Bologna, the Company’s Chairman and Chief Executive Officer, were recognized based on an accelerated vesting basis triggered by market conditions rather than a straight-line basis.

The Company accounts for equity instruments issued to non-employees in accordance with ASC 505, Equity . Under ASC 505, stock option awards issued to non-employees are measured at fair value using the Black-Scholes option-pricing model and recognized pursuant to a performance model.

8

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

2. Summary of Significant Accounting Policies - (continued)

Management Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates in these consolidated financial statements have been made for revenue, allowances for contractual and doubtful accounts, impairment of long-lived assets, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.

Long-lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates potential impairment by comparing the carrying amount of the asset with the estimated undiscounted future cash flows associated with the use of the asset and its eventual disposition. Should the review indicate that the assets cost is not recoverable, the carrying value of the asset would be reduced to its estimated fair value, which is measured by future discounted cash flows.

Foreign Currency Translation

The financial position and results of operations of the Company’s foreign subsidiary are determined using local currency as the functional currency. Assets and liabilities of these operations are translated at the exchange rate in effect at each period-end. Statement of Operations amounts are translated at the average rate of exchange prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss in stockholders’ equity (deficit).

Comprehensive Loss

The components of comprehensive loss are accumulated net loss and unrealized foreign currency translation adjustments for the three and nine months ended September 30, 2011 and 2012.

Fair Value of Financial Instruments

For cash and cash equivalents, accounts receivable, accounts payable, capital lease obligations and the line of credit the carrying amount approximates fair market value. Cash equivalents consist of money market accounts, with fair values estimated based on quoted market prices. For additional information see Note 12.

Advertising Costs

The Company markets its services through its advertising activities in trade publications and on-line. Advertising costs are included in selling and marketing expenses on the statements of operations and are expensed as incurred. Advertising costs for the three months ended September 30, 2011 and 2012 were $16,985 and $655, respectively and $83,462 and $13,626 for the nine months ended September 30, 2011 and 2012, respectively.

9

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

2. Summary of Significant Accounting Policies - (continued)

Concentration of Credit Risk and Clients and Limited Suppliers

Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All of the Company’s non-interest bearing cash balances were fully insured at September 30, 2012 due to a temporary federal program in effect from December 31, 2011 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning on January 1, 2013, federal insurance coverage is scheduled to revert to $250,000 per depositor at each financial institution, and the Company’s non-interest bearing cash balances may again exceed federally insured limits. There were no funds in interest-bearing accounts that exceeded the federally insured limits as of September 30, 2012. At September 30, 2012, $8,053 of cash was held outside of the United States and is uninsured.

Revenue sources that account for greater than 10 percent of total revenue are provided below.

	Three Months Ended September 30,										Nine Months Ended September 30,
	2011					2012					2011					2012
	(Unaudited)										(Unaudited)
	Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue
GlaxoSmithKline	$	356,594		7	%	$	777,571		14	%	$	2,878,860		16	%	$	1,000,147		8	%
GlaxoSmithKline Biologicals	$	1,109,112		22	%	$	886,945		16	%	$	4,186,385		24	%	$	1,619,372		12	%
Medicare, net of contractual allowances	$	1,572,807		31	%	$	1,227,893		23	%	$	4,029,676		23	%	$	3,995,200		30	%

Customers that account for greater than 10 percent of gross accounts receivable are provided below.

	As of December 31, 2011					As of September 30, 2012
	( Unaudited )					( Unaudited )
	Receivable Balance		Percent of Total Receivables			Receivable Balance		Percent of Total Receivables
GlaxoSmithKline	$	476,526		10	%	$	275,553		5	%
GlaxoSmithKline Biologicals	$	1,079,570		22	%	$	276,206		5	%
Medicare, net of contractual allowances	$	506,308		10	%	$	774,237		15	%

Many of the supplies and reagents used in the Company’s testing process are procured from a limited number of suppliers. Any supply interruption or an increase in demand beyond the suppliers’ capabilities could have an adverse impact on the Company’s business. Management believes it could identify alternative sources, if necessary, but it is possible such sources may not be identified in sufficient time to avoid an adverse impact on the Company’s business. Refer also to Note 6 for further discussion regarding these supply agreements. The Company purchases certain laboratory supplies and reagents primarily from two suppliers and purchases from these two companies accounted for approximately 76% and 71% of the Company’s reagent purchases for the three months ended September 30, 2011 and 2012, respectively and approximately 75% and 70% for the nine months ended September 30, 2011 and 2012, respectively.

10

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

3. Property and Equipment and Intangible Assets

Property and equipment and intangible assets consist of the following:

	December 31, 2011			September 30, 2012
				(Unaudited)
Laboratory equipment	$	3,036,274		$	3,208,449
Office furniture and equipment		624,859			660,626
Leasehold improvements		194,899			299,434
		3,856,032			4,168,509
Less: Accumulated depreciation		(2,810,745	)		(3,141,947	)
Total property and equipment, net	$	1,045,287		$	1,026,562
Purchased software	$	91,505		$	445,881
Internally developed software		48,461			108,362
		139,966			554,243
Less: Accumulated amortization		(73,151	)		(90,233	)
Total intangible assets, net	$	66,815		$	464,010

Intangible assets are carried at the cost to obtain them. Internally developed intangible assets are amortized using the straight-line method over the estimated useful life of five years. At September 30, 2012, the Company had not yet begun amortizing purchase software costs related to a new laboratory information management system because it had not yet been implemented. The Company expects to deploy the laboratory information management system in early 2013. Depreciation and amortization expense, included in cost of revenue, general and administrative expenses, and research and development expenses, for the three months ended September 30, 2011 and 2012 was $90,606 and $118,153, respectively, and $262,591 and $348,284 for the nine months ended September 30, 2011 and 2012, respectively.

Capital Lease

The Company leases certain equipment that is recorded as capital leases. This equipment is included in property and equipment on the accompanying balance sheet as of September 30, 2012 as follows:

	(Unaudited)
Equipment purchased under capital leases	$	451,234
Less: Accumulated amortization		(170,392	)
Equipment purchased under capital leases, net	$	280,842

Future minimum lease payments under capital leases as of September 30, 2012 are as follows:

Years ending December 31,	(Unaudited)
2012	$	44,907
2013		175,548
2014		87,119
Total minimum lease payments		307,574
Less amount represented by interest		(26,732	)
Less current portion		(158,821	)
Capital lease obligation, net of current portion	$	122,021

11

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

4. Loss Per Share

The Company calculates net loss per share in accordance with ASC 260, Earnings Per Share. Under the provisions of ASC 260, basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents then outstanding. Common stock equivalents consist of shares of common stock issuable upon the exercise of stock options and warrants.

The following table sets forth the computation for basic and diluted loss per share:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2012			2011			2012
	( Unaudited )						( Unaudited )
Numerator:
Net loss	$	(1,415,540	)	$	(1,415,488	)	$	(1,759,775	)	$	(7,269,739	)
Numerator for basic and diluted earnings per share	$	(1,415,540	)	$	(1,415,488	)	$	(1,759,775	)	$	(7,269,739	)
Denominator:
Denominator for basic and diluted earnings per share — weighted-average shares		19,537,232			26,362,842			18,979,010			24,709,185
Basic and diluted loss per share	$	(0.07	)	$	(0.05	)	$	(0.09	)	$	(0.29	)

Outstanding stock options and warrants to purchase 1,996,931 and 1,900,675 shares for the periods ended September 30, 2011 and 2012, respectively, were excluded from the calculation of diluted loss per share as their effect would have been antidilutive. All of the 100,000 warrants that were outstanding and exercisable had expired by September 30, 2012.

5. Commitments and Contingencies

Operating Leases

The Company leases 20,753 square feet of office and laboratory space in Los Angeles, California, under a noncancelable operating lease that will expire on June 30, 2013. The Company also leases 1,460 square feet of space in Frederick, Maryland, where administrative functions were performed until July 31, 2012. The Maryland lease expires on January 31, 2013. The Company moved the administrative functions performed out of this office primarily to its Los Angeles facilities and closed the Maryland office on July 31, 2012. The Company is working with the landlord of the Maryland office to find a replacement tenant for the space so that the Company can be released from its obligations under this lease.

Rent expense, which is classified in cost of revenue, general and administrative, and research and development expenses was $112,548 and $156,088 for the three months ended September 30, 2011 and 2012, respectively, and $371,553 and $508,456 for the nine months ended September 30, 2011 and 2012, respectively.

Future minimum lease payments by year and in the aggregate, under the Company’s noncancelable operating leases, consist of the following at September 30, 2012:

Years Ending December 31,	Unaudited
2012	$	161,780
2013		309,560
Total	$	471,340

12

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

5. Commitments and Contingencies – (continued)

Guarantees

The Company enters into indemnification provisions under its agreements with other counterparties in its ordinary course of business, typically with business partners, clients and landlords. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company's activities. These indemnification provisions generally survive termination of the underlying agreement. The Company reviews its exposure under these agreements no less than annually, or more frequently when events indicate. The Company believes the estimated fair value of these agreements is minimal as, historically, no payments have been made by the Company under these indemnification obligations. Accordingly, the Company has no liabilities recorded for these agreements as of December 31, 2011 and September 30, 2012.

Legal Matters

The Company is, from time to time, involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. These matters are not expected to have a material adverse effect upon the Company’s financial condition.

Employment Agreements

The Company has employment contracts with several individuals, which provide for annual base salaries and potential bonuses. These contracts contain certain change of control, termination and severance clauses that require the Company to make payments to certain of these employees if certain events occur as defined in their respective contracts.

6. License and Collaborative Agreements

License Agreement with the University of Southern California (“USC”)

In April 2000, as amended in June 2002 and April 2005, the Company entered into a license agreement with USC. Under this agreement, USC granted the Company a worldwide, exclusive license with the right to sublicense, the patents for RGI-1 and related technology, for use in human and veterinary diagnostic laboratory services, the sale of clinical diagnostic products, and the sale of research products to the research community. USC retains the right under the agreement to use the technology for research and educational purposes.

In consideration for this license, the Company agreed to pay USC royalties based on a percentage of the revenues generated by the use of RGI-1 and related technology.  Royalty expense relating to this agreement amounted to $123,873 and $98,740 for the three months ended September 30, 2011 and 2012, respectively and $382,685 and $231,180 for the nine months ended September 30, 2011 and 2012, respectively.  Such expense is included in cost of revenue in the accompanying statements of operations.

License Agreement with Roche Molecular Systems (“Roche”)

In November 2004, the Company entered into a non-exclusive license to use Roche’s PCR processes. In consideration for these rights, the Company is obligated to pay royalties to Roche, based on a percentage of net sales of products or services that make use of the PCR technology. Royalty expense included in cost of revenue relating to this agreement amounted to $116,867 and $105,170 for the three months ended September 30, 2011 and 2012, respectively and $425,232 and $249,057 for the nine months ended September 30, 2011 and 2012, respectively.

13

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

6. License and Collaborative Agreements - (continued)

Services Agreement with Taiho Pharmaceutical Co., Ltd. (“Taiho”)

In July 2001, the Company entered into an agreement with Taiho pursuant to which it will provide Taiho with RGI-1 generated molecular-based tumor analyses for use in guiding chemotherapy treatment for cancer patients and for use in its business developing and marketing pharmaceutical and diagnostic products for use against cancer. Pursuant to the agreement, the Company appointed Taiho as the exclusive purchaser in Japan of tests and testing services based upon the RGI-1 using gene expression for (i) any one or the combination of specified molecular markers, (ii) the therapeutic use of specified compounds, or (iii) the diagnosis or therapeutic treatment of specified precancerous and cancerous diseases. The Company also granted Taiho the right to be a non-exclusive purchaser in Japan of tests and testing services based upon the RGI-1 using gene expression, other than those for which Taiho has exclusivity, for, (i) any one or combination of molecular markers, (ii) the therapeutic use of any compound or biological product against cancer, or (iii) the diagnosis or therapeutic treatment of precancerous and cancerous diseases.

In consideration for the testing services provided, Taiho paid an upfront payment at the commencement of the agreement and is obligated to pay regular testing fees, covering the specific services performed on a monthly basis.  In January 2011, the Company amended its agreement with Taiho and the agreement was renewed for an additional three years. According to the terms of the renewal, Taiho’s appointment as an exclusive purchaser in Japan of certain tests and testing services and its minimum purchasing obligations ended on December 31, 2011.

Until its minimum purchasing obligations ended on December 31, 2011, Taiho was obligated to purchase a minimum amount of testing services from the Company each calendar quarter. Revenue recognized under this agreement was $158,500 and $585,625 for the three months ended September 30, 2011 and 2012, respectively and $803,600 and $1,122,425 for the nine months ended September 30, 2011 and 2012, respectively.

Services Agreement with GlaxoSmithKline, LLC formerly known as SmithKline Beecham Corporation (d.b.a. GlaxoSmithKline or “GSK”)

In January 2006, the Company entered into a master services agreement with GSK, a leading pharmaceutical manufacturer, pursuant to which the Company provides services in connection with profiling the expression of various genes from a range of human cancers. Under the agreement, the Company will provide GSK with testing services as described in individual protocols and GSK will pay the Company for such services based on the pricing schedule established for each particular protocol. GSK is obligated to make minimum annual payments to the Company under the agreement and also was obligated to make a non-refundable upfront payment to the Company, to be credited against work undertaken pursuant to the agreement. In January 2006, the Company received an upfront payment of $2,000,000, which was initially recorded as deferred revenue. There was no remaining deferred revenue balance associated with this agreement as of December 31, 2011.

In December 2008, the Company amended and restated its master services agreement with GSK and extended the term of the agreement for a two-year period, with the option for the parties to extend the agreement for additional one-year periods, upon their mutual written agreement. In addition, the Company became a preferred provider to GSK and its affiliates of genetic testing services on a fee-for-service basis and, in anticipation of the services to be provided, GSK agreed to make a non-refundable upfront payment of approximately $1,300,000, which was received in January 2010.  There was no amount of deferred revenue balance associated with this agreement as of December 31, 2011.

The Company recognized revenue of $356,594 and $777,571 relating to the GSK agreement for the three months ended September 30, 2011 and 2012, respectively and $2,878,860 and $1,000,147 for the nine months ended September 30, 2011 and 2012, respectively.

Non-Exclusive License Agreement with GSK

In March 2010, the Company entered into a non-exclusive license agreement with GSK.  Under the agreement, the Company granted GSK a non-exclusive, sublicenseable license to its proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples.  As part of the agreement, the Company received a non-refundable technology access fee in consideration for the transfer of the Company’s technology to GSK. The agreement also contains milestone provisions which would allow the Company to earn further payments from GSK.  As of September 30, 2012, the Company had earned a $500,000 milestone payment from GSK.

14

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

6. License and Collaborative Agreements - (continued)

Master Services Agreement with GlaxoSmithKline Biologicals S.A. (“GSK Bio”)

On July 26, 2012, the Company entered into a second amended and restated master services agreement with GSK Bio, the vaccine division of GSK. Pursuant to this agreement, which has an effective date of May 15, 2012, the Company will provide testing services for clinical trials and epidemiology studies relating to GSK Bio’s cancer immunotherapies. The Company will perform these testing services on a fee-for-service basis as embodied in written task orders. The agreement will expire on December 31, 2014, and is terminable by GSK Bio, without cause, upon 90 days’ written notice to the Company.

The Company recognized revenue of $1,109,112 and $886,945 relating to the services performed for GSK Bio for the three months ended September 30, 2011 and 2012, respectively, and $4,186,385 and $1,619,372 for the nine months ended September 30, 2011 and 2012.

Collaboration Agreement with Shanghai BioChip Company, Ltd. (“SBC”)

On March 5, 2007, the Company entered into a collaboration agreement with SBC pursuant to which SBC provides exclusive testing services to the Company’s clients in China.

Pursuant to the agreement, the Company has granted SBC an exclusive license in China to provide services in China using the Company’s proprietary RNA extraction technologies. Subject to consent from USC, the Company granted SBC an exclusive sublicense to patents licensed from USC for distribution of testing services in China. In turn, SBC performs RNA extraction from formalin-fixed paraffin-embedded (“FFPE”) tissue specimens exclusively for the Company during the term of the agreement.

This agreement had an initial term of five years, with an automatic renewal for an additional three-year term unless either party gives 90 days’ notice in advance of the renewal date of its intent not to renew. As neither party gave notice of intent not to renew, the agreement has automatically renewed for a successive three year period. Pursuant to the agreement, SBC receives a percentage of the gross margin, as defined in the agreement, collected from the Company’s clients in China as compensation for its testing services performed. For the three months ended September 30, 2011 testing services totaled $84,275, and there were no testing services for the three months ended September 30, 2012. Testing services totaled $234,512 for the nine months ended September 30, 2011, and there were no testing services for the nine months ended September 30, 2012.

Commission Agreement with Hitachi Chemical Co., Ltd.

On July 26, 2007, the Company entered into a collaboration agreement with Hitachi Chemical Co., Ltd. (“Hitachi”), a leading diagnostics manufacturer in Japan. Under the terms of this agreement, Hitachi uses the Company's proprietary and patented techniques to extract genetic information from FFPE tissue samples collected in Southeast Asia, Australia and New Zealand. As part of this collaboration agreement, the Company provides Hitachi with the technical information and assistance necessary to perform the testing services. Hitachi is responsible for expenses related to the cost of laboratory equipment and modification to the laboratory facilities, as well as the cost of reagents. The Southeast Asian countries covered under this agreement include Japan, North Korea, South Korea, Taiwan, Mongolia, Pakistan, Bangladesh, Sri Lanka, Nepal, Singapore, Malaysia, Indonesia, Brunei, Thailand, Myanmar, Laos, Cambodia, Vietnam and the Philippines (the “Territory”).

The collaboration agreement had an initial term expiring on June 30, 2010, with an automatic renewal for one year at the end of the original period under the same terms and conditions. Pursuant to the agreement, Hitachi performs certain testing services and receives a percentage of the revenue collected from the Company's clients in the Territory, which totaled $106,260 and $291,728 for the three months ended September 30, 2011 and 2012, respectively and $481,951 and $526,057 for the nine months ended September 30, 2011 and 2012, respectively. Due to the closing of Hitachi’s applicable facility in the Territory, the Company and Hitachi have agreed to terminate this agreement effective September 30, 2012 pending delivery of certain outstanding items by Hitachi.

15

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

7. Stock Option Plans

In March 2000, the Company adopted a Stock Option Plan (the “2000 Stock Plan”) as approved by its Board of Directors. Under the 2000 Stock Plan, the Company granted options to acquire up to 1,600,000 shares of common stock. In connection with the adoption of the 2006 Employee, Director and Consultant Stock Plan, as further discussed below, the Company is to grant no additional options under the 2000 Stock Plan. Under the 2000 Stock Plan, there were no options to purchase shares that remained outstanding as of September 30, 2012. No more options may be granted under the 2000 Stock Plan. The Company also granted options to purchase 16,000 shares of common stock to two consultants which were granted under separate agreements outside of the 2000 Stock Plan.

On October 26, 2006, the Board of Directors of the Company approved, and on May 1, 2007, reapproved the adoption of the 2006 Employee, Director and Consultant Stock Plan (the “2006 Stock Plan”). The stockholders approved the 2006 Stock Plan on June 1, 2007. The initial number of shares which may be issued from time to time pursuant to the 2006 Stock Plan was 2,160,000 shares of common stock.  In addition, on the first day of each fiscal year of the Company during the period beginning in fiscal year 2008, and ending on the second day of fiscal year 2017, the number of shares that may be issued from time to time pursuant to the 2006 Stock Plan is increased by the lesser of (i) 200,000 shares or equivalent, after determination of the effect of any stock split, stock dividend, combination or similar transactions as set forth in the 2006 Stock Plan, (ii) 5% of the number of outstanding shares of common stock of the Company on such date or (iii) an amount determined by the board of directors of the Company.  The initial number of shares available for issuance of 2,160,000 increased by 200,000 in 2008, 2009, 2010, 2011 and 2012, resulting in the total number of shares that may be issued as of January 1, 2012 to be 3,160,000.  As of September 30, 2012, there were 1,059,325 options available for grant under the 2006 Stock Plan.

Employee options vest according to the terms of the specific grant and expire 10 years from the date of grant. Non-employee option grants to date typically vest over a 2 to 3 year period. The Company had 1,900,675 options outstanding at a weighted average exercise price of $2.29 at September 30, 2012. There were 1,135,003 non-vested stock options outstanding with a weighted average grant date fair value of $1.05 at September 30, 2012.  As of September 30, 2012, there was $886,077 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 Stock Plan. That cost is expected to be recognized over a weighted-average period of 2.47 years.

Except for the certain grants of restricted common stock and common stock options containing market conditions as described below, the Company estimated share-based compensation expense for the three months ended September 30, 2011 and 2012 using the Black-Scholes model with the following weighted average assumptions:

	Three Months Ended September 30,
	2011		2012
Risk free interest rate		—		0.79 - 0.80	%
Expected dividend yield		—		—
Expected volatility		—		72.35	%
Expected term **(in years)		—		6.02
Forfeiture rate		—		7.00	%

** Expected term is calculated using SAB 107, Simplified Formula. Management has concluded that the use of the simplified method for calculating the expected term of its common stock option grants is appropriate given the Company’s lack of history of option exercises.

The following table summarizes the stock option activity for the 2006 Plan for the nine months ended September 30, 2012:

	Number of Shares			Weighted Average Exercise Price		Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2011		1,870,846		$	3.67		7.40	$	66,976
Granted (Unaudited)		914,200		$	1.47		9.64		63,541
Exercised (Unaudited)		—		$	—		—		—
Expired (Unaudited)		(701,840	)		5.02		5.56		—
Forfeited (Unaudited)		(182,531	)	$	1.83		—		—
Outstanding, September 30, 2012 (Unaudited)		1,900,675		$	2.29		9.29	$	63,541
Exercisable, September 30, 2012 (Unaudited)		765,672		$	3.38		6.78	$	2,649

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2011 and 2012 was $2.27 and $1.47, respectively.   

16

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

7. Stock Option Plans – (continued)

The following table provides additional information regarding options outstanding under the 2006 Plan as of September 30, 2012 (Unaudited):

		Options Outstanding				Options Exercisable
Exercise Price		Number of Options		WA Remaining Contractual Term		Number of Options		WA Remaining Contractual Term
$	1.16 to 1.17		490,700		9.83		20,459		9.83
	1.32 to 1.35		196,316		7.09		141,233		6.71
	1.65 to 1.67		327,750		9.22		5,210		9.66
	1.86 to 2.06		220,000		9.49		16,044		9.48
	2.21 to 2.35		285,500		8.10		235,500		8.21
	2.71 to 3.24		172,409		6.83		139,226		6.60
	3.80 to 4.29		23,000		5.20		23,000		5.20
	7.00		185,000		4.69		185,000		4.69
			1,900,675		8.31		765,672		6.78

Stock-based compensation expense was classified as follows in the results of operation:

	Three Months Ended September 30,				Nine Months Ended September 30,
	( Unaudited )				( Unaudited )
	2011		2012		2011		2012
Cost of revenue	$	61,395	$	12,603	$	208,672	$	46,839
Research and development		10,951		17,167		37,221		29,591
Sales and marketing		5,521		11,277		18,765		39,337
General and administrative		128,852		121,466		439,113		568,130
Totals	$	206,719	$	162,513	$	703,771	$	683,897

Thomas Bologna was appointed Chief Executive Officer of the Company on December 21, 2011, and in connection with his appointment, Mr. Bologna was awarded stock options outside of the 2006 Stock Plan. Pursuant to the employment agreement between the Company and Mr. Bologna, dated December 21, 2011, and in reliance on NASDAQ Listing Rule 5636(c), the Company granted Mr. Bologna (i) a stock option to purchase 600,000 shares of the Company’s common stock, which vests monthly over 36 months from the date of grant, subject to his continued employment with the Company, (ii) a stock option to purchase 300,000 shares of the Company’s common stock, which vests in two equal installments on the first day of the 18th and 36th calendar months from the date of grant, subject to his continued employment with the Company, or if earlier, the date on which the 30-day trailing average closing price of the Company’s common stock equals or exceeds $1.80, and (iii) 270,000 shares of restricted shares of common stock of the Company, which vest on the date on which the 30-day trailing average closing price of the Company’s common stock equals or exceeds $2.40. The exercise price of the stock options is $1.20 per share, the closing price of the Company’s common stock on the day prior to the date of grant. The expense recognized in connection with these grants was $104,468 and $440,133 for the three and nine months ended September 30, 2012, respectively, and is included in the above table.

17

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

7. Stock Option Plans – (continued)

Since the restricted shares of common stock grant vests upon attainment of a target price for the Company’s common stock and each tranche of the 300,000 share common stock option grant can vest sooner than the stated vesting dates based upon attainment of a target price for the Company’s common stock, these awards are deemed to include market conditions for purposes of determining the valuation and accounting for the awards. Accordingly, the fair value of the restricted shares of common stock grant and each tranche of the 300,000 share common stock option grant that Mr. Bologna received was determined using a Monte-Carlo simulation model to simulate the Company’s stock prices in the future that would trigger or not trigger the market conditions. For these awards containing market conditions, the compensation amount will be attributed over the service date unless vesting occurs sooner due to achieving the market condition.

The following table summarizes the awards to Mr. Bologna:

Type	Grant Date		Number of Awards		Intrinsic Value as of September 30, 2012		Exercise Price		Options Exercisable		Remaining Contractual Term
Restricted Shares of Common Stock		12/21/2011		270,000	$	13,500	$	—		—		9.2
Options		12/21/2011		600,000	$	30,000	$	1.20		150,000		9.2
Options		12/21/2011		300,000	$	15,000	$	1.20		300,000		9.2

During the first quarter of 2012, Mr. Bologna’s stock award of 300,000 shares met the conditions for vesting in that the 30-day trailing average closing price of the Company’s common stock exceeded $1.80. The Company recognized expense of $129,000 for the vesting of this tranche of options for Mr. Bologna’s stock awards during the quarter ended March 31, 2012.

8. Common Stock Warrants

The Company issues warrants to purchase common shares of the Company either as compensation for services or as additional incentive for investors who may purchase common stock. The value of warrants issued for compensation is accounted for as a non-cash expense to the Company at the fair value of the warrants issued.

In June 2007, in conjunction with the initial public offering, the Company issued 100,000 warrants to purchase 100,000 shares of its common stock at an exercise price of $7.70 to the underwriters as part of the initial public offering. There were no warrants granted during the three months ended September 30, 2011 and 2012.  As of September 30, 2012, all of the warrants that were outstanding and exercisable had expired.

18

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

9. Income Taxes

Deferred income taxes result from temporary differences between income tax and financial reporting computed at the effective income tax rate. The Company has established a valuation allowance against its net deferred tax asset due to the uncertainty surrounding the realization of such asset. Management periodically evaluates the recoverability of the deferred tax assets. At such time it is determined that it is more likely than not that deferred tax assets are realizable, the valuation allowance will be reduced.

The Company files U.S. federal, U.S. state, and foreign tax returns. The Company’s major tax jurisdictions are U.S. federal and the State of California. The Company is subject to tax examinations for the open years from 2002 through 2011.

10. Segment Information

The Company operates in a single reporting segment, with an operating facility in the United States.

The following enterprise wide disclosure was prepared on a basis consistent with the preparation of the consolidated financial statements. The following tables contain certain financial information by geographic area:

	Three Months Ended September 30,				Nine Months Ended September 30,
Net Revenue:	2011		2012		2011		2012
	(Unaudited)				(Unaudited)
United States	$	3,833,037	$	3,890,842	$	12,740,800	$	10,310,236
Europe		1,109,112		893,060		4,186,385		1,672,387
Japan		158,500		619,635		803,600		1,237,565
	$	5,100,649	$	5,403,537	$	17,730,785	$	13,220,188

Long-lived assets:	December 31, 2011		September 30, 2012
			(Unaudited)
United States	$	1,112,102	$	1,490,572

19

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

11. Sale of Common Stock

May 2011 Registered Offering of Common Stock

On May 6, 2011, the Company issued 1,175,512 shares of its common stock at a price of $1.99 per share in a registered direct public offering to certain institutional investors and received net proceeds of approximately $2.2 million from the sales, after deducting its estimated offering expenses. The securities issued with this financing were registered under the Securities Act of 1933, as amended. The shares were issued pursuant to a prospectus supplement dated May 4, 2011 and an accompanying prospectus dated January 6, 2011, pursuant to the Company’s existing effective shelf registration statement on Form S-3 (File No. 333-171266), which was filed with the Securities and Exchange Commission on December 17, 2010 and declared effective by the SEC on January 6, 2011.

Common stock classified outside of stockholders’ equity (deficit)

March 2010 Private Placement

On March 5, 2010, the Company entered into a purchase agreement with certain affiliates of and funds managed by Lansdowne Partners Limited Partnership (“Lansdowne”), Greenway Capital Partners and Paragon Associates for the private placement of 3,005,349 newly-issued shares of the Company’s common stock at a per share price of $1.31.  The closing of the sale of the shares occurred on March 5, 2010.  In connection with the acquisition of the shares, the purchasers were granted certain preemptive rights permitting them to maintain their percentage ownership interests in connection with future issuances of the Company’s capital stock, subject to various exceptions and limitations.  Lansdowne participated in the private placement by electing to exercise the preemptive rights granted to it pursuant to the purchase agreement by and between the Company and Lansdowne, dated July 22, 2009. Net proceeds received from this financing were approximately $3,879,403.

In connection with the private placement, the Company also entered into a registration rights agreement, dated March 5, 2010, with the purchasers pursuant to which it agreed to file, within 45 days of the closing of the private placement, a registration statement with the SEC to register the shares for resale, which registration statement was required to become effective within 120 days following the closing.  The Company also granted certain "piggyback" registration rights to the purchasers which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more shareholders until the earlier of the sale of all of the shares or the shares becoming eligible for sale under Rule 144(b)(1) without restriction.

Pursuant to the registration rights agreement, dated March 5, 2010, the Company filed a registration statement with the SEC to register the 3,005,349 shares sold to Lansdowne, Greenway and Paragon for resale, which became effective on May 19, 2010 and which registration statement remained effective as of September 30, 2012.

Under the registration rights agreements with the purchasers, the Company is obligated to use commercially reasonable efforts to (i) cause the registration statement described above to remain continuously effective and (ii) to maintain the listing of Company’s common stock on NASDAQ or other exchanges, as defined, for a period that will terminate on the earlier of March 5, 2013 or the date on which the purchasers have sold all shares of common stock.  The Company is also required to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  In the event the Company fails to satisfy its obligations under the registration rights agreements, the Company would be in breach of said agreements, in which event, the purchases would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. These registration rights agreements do not provide an explicitly stated or defined penalty due upon a breach.  Because (i) the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements and (ii) complying with all filing requirements under the Exchange Act as described above is not solely within the Company’s control, the Company  is required to present the investment of approximately $3,879,403 in the Company’s common stock as common stock outside of stockholders’ equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities .

On January 18, 2012, the Company removed the restrictions on 3,658,676 shares purchased by Lansdowne and reclassified the shares to common stock from common stock classified outside of equity(deficit).

20

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

11. Sale of Common Stock – (continued)

February 2012 Private Placement

On February 2, 2012, the Company entered into purchase agreements with various investors (collectively, the “February Investors”) for the private placement of an aggregate of 5,257,267 newly-issued shares of the Company’s common stock (the “February Shares”) at a purchase price of $1.50 per share (the “February 2012 Private Placement”). Net cash proceeds raised in the February 2012 Private Placement were approximately $7,822,000. The February Investors participating in the February 2012 Private Placement were various institutions and all officers and directors of the Company. The final closing of the February 2012 Private Placement (the “February Closing”) occurred on February 2, 2012.

In connection with the February 2012 Private Placement, the Company also entered into registration rights agreements, each dated February 2, 2012, with the February Investors pursuant to which the Company agreed to file, within 90 days of the February Closing, a registration statement with the SEC to register the February Shares for resale, which registration statement is required to become effective within 180 days following the February Closing. The Company also granted the February Investors certain “piggyback” registration rights, which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more shareholders until the earlier of the sale of all of the February Shares or the February Shares becoming eligible for sale under Rule 144(b)(1) without restriction.

Pursuant to the registration rights agreements dated February 2, 2012, the Company filed a registration statement with the SEC on April 30, 2012, to register the February Shares for resale. This registration statement became effective on May 17, 2012 and remained effective as of September 30, 2012.

Under the registration rights agreements with the February Investors, the Company is obligated to use commercially reasonable efforts to (i) cause the registration statements described above to remain continuously effective and (ii) to maintain the listing of Company’s common stock on NASDAQ or other exchanges, as defined, for a period that will terminate on the earlier of February 2013, or the date on which the February Investors have sold all shares of common stock.  The Company is also required to file with the SEC in a timely manner all reports and other documents required of the Company required of the Company under the Exchange Act.  In the event the Company fails to satisfy its obligations under the registration rights agreements, the Company would be in breach of said agreements, in which event, the February Investors would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. These registration rights agreements do not provide an explicitly stated or defined penalty due upon a breach.  Because (i) the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements and (ii) complying with all filing requirements under the Exchange Act as described above is not solely within the Company’s control, the Company  is required to present the investment of approximately $7,884,400 in the Company’s common stock as common stock outside of stockholders’ equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities.

September 2012 Private Placement

On September 13, 2012, the Company entered into a purchase agreement (the “Purchase Agreement”) with Glaxo Group Limited, an affiliate of GSK (the “GSK Investor”) and two existing investors, Swiftcurrent Partners, L.P. and Swiftcurrent Offshore, Ltd. (collectively with the GSK Investor, the “September Investors”) for the private placement of an aggregate of 8,000,000 newly-issued shares of the Company’s common stock (the “September Shares”) at a purchase price of $1.10 per share (the “September 2012 Private Placement”). The Company raised gross cash proceeds of $8,800,000 in the September 2012 Private Placement which closed (the “Closing”) on September 13, 2012.

Pursuant to the Purchase Agreement, for so long as the GSK Investor or its affiliates own at least 50% of the September Shares it purchased pursuant to the Purchase Agreement, the GSK Investor has the right to designate one non-voting board observer (the "Board Observer"). The Board Observer, if appointed, has the right to attend all meetings of the Board of Directors of the Company and to receive all board meeting materials, subject to certain restrictions set forth in the Purchase Agreement. As of the date hereof, the GSK Investor has not exercised its right to designate the Board Observer.

In connection with the September 2012 Private Placement, the Company also entered into a registration rights agreement, dated September 13, 2012 (the “September Registration Rights Agreement”), with the September Investors pursuant to which the Company agreed to file, within 45 days of the Closing, a registration statement with the SEC to register the September Shares for resale, which registration statement is required to become effective within 180 days following the Closing. The Company also granted the September Investors certain “piggyback” registration rights, which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more stockholders until the earlier of the sale of all of the September Shares or the September Shares becoming eligible for sale under Rule 144(b)(1) without restriction.

21

RESPONSE GENETICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

11. Sale of Common Stock – (continued)

Under the September Registration Rights Agreement, the Company is obligated to use commercially reasonable efforts to cause a registration statement to become effective and to remain continuously effective and to maintain the listing of the covered common stock on NASDAQ or other exchanges, as defined, for a period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration Statement as amended from time to time, have been sold, (ii) the date on which there are no longer any Registrable Securities outstanding or (iii) three years from the date of filing of such Registration Statement (the “ Effectiveness Period ”) and advise each September Investor in writing when the Effectiveness Period has expired. “Registrable Securities” means (i) the September Shares and (ii) shares of capital stock or any other securities issued or issuable with respect to or in exchange for the September Shares; provided, that, a security shall cease to be a Registrable Security with respect to a September Investor upon (A) sale by such September Investor pursuant to a registration statement or Rule 144 under the 1933 Act, or (B) such security becoming eligible for sale by such September Investor without restriction pursuant to Rule 144(b)(1).   In the event the Company fails to satisfy its obligations under the September Registration Rights Agreement, the Company would be in breach of such agreement, in which event, the September Investors would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. The September Registration Rights Agreement does not provide an explicitly stated or defined penalty due upon a breach.  Because the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements, the Company  is required to present the investment of approximately $8,800,000 in the Company’s common stock as common stock outside of stockholders’ equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities.

Pursuant to the September Registration Rights Agreement, the Company filed a registration statement with the SEC on October 26, 2012, to register the September Shares for resale. This registration statement became effective on November 13, 2012.

As of December 31, 2011 and September 30, 2012, a total of $7,854,682 and $19,575,724 of common stock was classified outside of stockholders’ equity (deficit), respectively.

12. Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information.  ASC 820 establishes a three-level valuation hierarchy of valuation techniques that is based on observable and unobservable inputs. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The first two inputs are considered observable and the last unobservable, that may be used to measure fair value and include the following:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of September 30, 2012, the Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis, including its cash and cash equivalents. The fair value of these assets and liabilities was determined using the following inputs in accordance with ASC 820 at September 30, 2012:

	Fair Value Measurement as of September 30, 2012 (Unaudited)
	Total		Level 1		Level 2		Level 3
Description	$		$		$		$
Money market accounts (1)		10,000		10,000		-		-

(1) Included in cash and cash equivalents on the accompanying consolidated balance sheet.

13. Subsequent Events

As described above, pursuant to the registration rights agreement, dated September 13, 2012, the Company filed a registration statement with the SEC on October 26, 2012, to register for resale 8,000,000 shares of common stock of the Company issued to certain investors on September 13, 2012. This registration statement became effective on November 13, 2012.

22

Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations

Special Note Regarding Forward Looking Statements

Except for the historical information contained herein, this Quarterly Report on Form 10-Q contains or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. When used in this report, the words “expects,” “anticipates,” “intends,” “estimates,” “plans,” “may,” “will,” “believes,” and similar expressions are intended to identify forward-looking statements although not all forward-looking statements contain these identifying words. These are statements that relate to future periods and include statements about our expectation that, for the foreseeable future, a significant amount of our revenues will be derived from ResponseDX^® sales; our ability to maintain revenue from pharmaceutical clients; the factors that may impact our financial results; the extent of our net losses and our ability to achieve sustained profitability; our business strategy and our ability to achieve our strategic goals; our expectations regarding revenues from ResponseDX® products; the amount of future revenues that we may derive from Medicare patients; the potential or intent to enter into distribution arrangements; our ability to sustain or increase demand for our tests; our sales forces’ capacity to sell our tests; plans for the development of additional tests; our expectation that our research and development, general and administrative and sales and marketing expenses will increase and our anticipated uses of those funds; our ability to comply with the requirements of a public company; our ability to attract and retain qualified employees; our compliance with federal and state regulatory requirements; the potential impact resulting from the regulation of our tests by the U.S. Food and Drug Administration; the impact of new or changing policies or regulation of our business; our belief that we have filed adequate patent and trademark applications to protect our intellectual property rights; the impact of accounting pronouncements and our accounting policies, estimates, assumptions or models on our financial results; and anticipated challenges to our business.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expected. These risks and uncertainties include, but are not limited to, our ability to develop and commercialize new product without unanticipated delay; the risk that we may not maintain reimbursement for our existing tests or any future tests; the risk that reimbursement pricing may change; the risks and uncertainties associated with the regulation of our tests; our ability to compete;; our ability to obtain capital when needed; and our history of operating losses. These forward-looking statements speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes to the financial statements included elsewhere in this Quarterly Report on Form 10-Q as of September 30, 2012 and our audited financial statements for the year ended December 31, 2011 included in our Annual Report on Form 10-K previously filed with the Securities and Exchange Commission. This discussion contains forward-looking statements that relate to future events or our future financial performance. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward looking statements.

Overview

Response Genetics, Inc. was formed as a Delaware corporation in September 1999. We are a life sciences company engaged in the research and development and commercialization of clinical diagnostic tests for cancer. Our mission is to provide personalized genetic information that will help guide physicians and patients in choosing the treatment from which a given patient is most likely to benefit. We currently generate revenues primarily from sales of our ResponseDX^® diagnostic tests, which we launched in 2008, and by providing clinical trial testing services to pharmaceutical companies.

Our proprietary technologies enable us to reliably and consistently extract the nucleic acids RNA and DNA from tumor specimens that are stored as formalin-fixed and paraffin-embedded, or FFPE, specimens and thereby to analyze genetic information contained in these tissues. Our technologies also enable us to use the FFPE patient biopsies for the development of diagnostic tests.

We file our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other information with the SEC. Copies of these reports are also available through our website at www.responsegenetics.com. We also post copies of our press releases on our corporate website.

Our Approach

Clinical studies have shown that not all cancer therapy works effectively in every patient, and that a number of patients receive therapy that has no benefit to them and may potentially even be harmful. Our goal is to provide physicians and cancer patients with a means to make informed, individualized treatment decisions based on genetic analysis of tumor tissues through the utilization of our proprietary technology as well as through the use of non-proprietary technology that could also benefit patients.

Our approach to achieving this goal is to provide a range of oncology diagnostic testing services, focusing on solid tumors, which include technical laboratory services and professional interpretation of laboratory test results by licensed pathologists. In addition, we provide services to pharmaceutical companies and research organizations, including development of diagnostics and clinical trial testing services.

23

ResponseDX^®

The outcome of cancer chemotherapy is highly variable due to genetic differences among patients. Some patients respond well with tumor shrinkage and increase in life span. Other patients do not obtain benefit from the same therapy but may still experience toxic side effects as well as delay in effective treatment and psychological trauma.

Many therapy regimens are administered without any pre-selection of patients on the basis of their particular genetics. However, recent development of very sensitive molecular technologies has enabled researchers to identify and measure genetic factors in patients’ tissues that can predict the probability of success or failure of many currently used anti-cancer agents. In order to increase the chances of a better therapy outcome for cancer patients, we have and continue to develop genetic tests that measure predictive factors for tumor response in tumor tissue samples. We offer tests for non-small cell lung cancer, colorectal cancer and gastric and gastroesophageal, and melanoma cancer patients’ tumor tissue specimens through our ResponseDX: Lung^®, ResponseDX: Colon^® and ResponseDX: Gastric^® and ResponseDX: Melanoma^® test suites. These test results may help doctors and patients decide the best course of treatment for patients.

Our ResponseDX^® tests are commercially available through our laboratory located in Los Angeles, California, which is certified under the Clinical Laboratory Improvement Amendment of 1988.

Diagnostic Tests for Other Cancers

In addition to ResponseDX:Lung^®, ResponseDX:Colon^®, and ResponseDX: Gastric^® and ResponseDX: Melanoma^®, we are developing and intend to commercialize tests for other types of cancer that identify genetic profiles of tumors that are more aggressive and recur rapidly after surgery. We also are identifying genetic profiles of tumors that are more or less responsive to a particular therapy. Following the development of tests to predict the risk of recurrence after surgery, we intend to develop tests to determine the most active therapy regimen for the individual patient at risk. Once developed and after obtaining any necessary regulatory approvals, we intend to leverage our relationships in the healthcare industry to market, sell or license these tests as a means for physicians to determine the courses of cancer treatment.

Pursuit of Additional Collaborations and In-licensing to Expand Our Business

We intend to pursue additional collaborations with pharmaceutical companies or in-licensing of products or technologies that will enable us to accelerate the implementation of our plans to expand the services we provide to oncologists and pathologists. We expect to implement this plan by way of licensing of technology and know-how, investments in other companies, strategic collaborations, and other similar transactions. We expect these collaborations to provide us with early access to new technologies available for commercialization.

There are no assurances that we will be able to continue making our current ResponseDX^® tests available, or make additional ResponseDX^® tests available; that we will be able to develop and commercialize tests of other types of cancer; or that we will be able to expand our testing service business.

We anticipate that over the next 12 months, a substantial portion of our capital resources and efforts will be focused on research and development to expand our series of diagnostic tests for cancer patients, sales and marketing activities related to our ResponseDX^® diagnostic tests, and for other general corporate purposes.

Research and development expenses represented 7.0% and 6.2% of our total operating expenses for the three months ended September 30, 2011 and 2012, respectively and 4.3% and 8.3% for the nine months ended September 30, 2011 and 2012, respectively. Major components of the $452,734 and $426,105 in research and development expenses for the three months ended September 30, 2011 and 2012, and $838,622 and $1,695,851 for the nine months ended September 30, 2011 and 2012, respectively, include supplies and reagents for our research activities, personnel costs, occupancy costs, equipment warranties and service, patent fees, insurance, business consulting and sample procurement costs.

24

Critical Accounting Policies and Significant Judgments and Estimates

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as revenues and expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from those estimates under different assumptions or conditions. We believe the following critical accounting policies reflect our more significant estimates and assumptions used in the preparation of our financial statements.

Revenue Recognition

Pharmaceutical Revenue

Revenues that are derived from testing services provided to pharmaceutical companies are recognized on a contract specific basis pursuant to the terms of the related agreements. Revenue is recognized in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.

Revenues are recorded on an accrual basis as the contractual obligations are met and as a set of assays is processed through the Company’s laboratory under a specified contractual protocol and are recorded on the date the tests are resulted. Certain contracts have minimum assay requirements that, if not met, result in payments that are due upon the completion of the designated period. In these cases, revenues are recognized when the end of the specified contract period is reached, if the minimum assay requirements are not met.

ResponseDX^® Revenue

Net revenue for the Company’s diagnostic services is recognized on an accrual basis at the time discreet diagnostic tests are completed. Each test performed relates to a specimen encounter derived from a patient, and received by the Company on a specific date (such encounter is commonly referred to as an “accession”). The Company’s services are billed to various payors, including Medicare, private health insurance companies, healthcare institutions, and self-pay patients. The Company reports net revenue from contracted payors, including certain private health insurance companies, and healthcare institutions based on the contracted rate, or in certain instances, the Company’s estimate of the amount expected to be collected for the services provided. For billing to Medicare, the Company uses the published fee schedules, net of standard discounts (commonly referred to as “contractual allowances”). The Company reports net revenue from non-contracted payors, including certain private health insurance companies, based on the amount expected to be collected for the services provided.

The Company has its Medicare provider number which allows it to invoice and collect from Medicare. Invoicing to Medicare is primarily based on amounts allowed by Medicare for the service provided as defined by Common Procedural Terminology codes.

License Fees

We have licensed technology for the extraction of RNA and DNA from FFPE tumor specimens from USC in exchange for royalty fees on revenue generated by use of this technology. These royalties are calculated as a fixed percentage of revenue that we generate from use of the technology licensed from USC. Total license fees expensed in cost of revenue under the royalty agreement to USC were $123,873 and $98,740 for the three months ended September 30, 2011 and 2012, respectively and $382,685 and $231,180 for the nine months ended September 30, 2011 and 2012, respectively. We also maintain a non-exclusive license to use Roche’s PCR processes. We pay Roche a fixed percentage royalty fee for revenue that we generate through use of this technology. Royalties expensed in cost of revenue under this agreement totaled $116,867 and $105,170 for the three months ended September 30, 2011 and 2012, respectively and $425,232 and $249,057 for the nine months ended September 30, 2011 and 2012, respectively.

We are subject to potentially significant variations in royalties recorded in any period. While the amount paid is based on a fixed percentage from revenues of specific tests pursuant to terms set forth in the agreements with USC and Roche, the amount due is calculated based on the revenue we recognize using the respective licensed technology. As discussed above, this revenue can vary from period to period as it is dependent on the timing of the specimens submitted by our clients for testing.

25

Accounts Receivable and Allowance for Doubtful Accounts

We invoice our pharmaceutical clients as specimens are processed and any other contractual obligations are met. Our contracts with pharmaceutical clients typically require payment within 45 days of the date of invoice. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our clients to make required payments. We specifically analyze accounts receivable and historical bad debts, client credit, current economic trends and changes in client payment trends when evaluating the adequacy of the allowance for doubtful accounts. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered. To date, our pharmaceutical clients have primarily been large pharmaceutical companies. As a result, bad debts to date have been minimal and there is no allowance for doubtful accounts for our pharmaceutical revenue at September 30, 2011 and 2012.

We bill Medicare and Private Payors for ResponseDX^® upon completion of the required testing services. As such, we take assignment of benefits and the risk of collection with Medicare and Private Payors. We continue to monitor the collection history for Medicare and Private Payors.  Based on the historical experience for our Medicare and Private Payor accounts, we have determined that related accounts receivable associated with billings over one year old are unlikely to be collected.

An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from the Company’s various payor groups. The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically, and is principally based upon an evaluation of historical collection experience of accounts receivable for the Company’s various payor classes. After appropriate collection efforts, accounts receivable are written off and deducted from the allowance for doubtful accounts. Additions to the allowance for doubtful accounts are charged to bad debt expense. The payment realization cycle for certain governmental and managed care payors can be lengthy involving denial, appeal, and adjudication processes, and is subject to periodic adjustments that may be significant. Therefore, we have recorded an allowance for doubtful accounts of $838,750 as of December 31, 2011 and $864,419 as of September 30, 2012.

We cannot guarantee that we will continue to experience the same credit loss rates that we have in the past. Measurement of such losses requires consideration of historical loss experience, including the need to adjust for current conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and financial health of specific customers. We consider all available information in our assessments of the adequacy of the reserves for uncollectible accounts.

Income Taxes

We estimate our tax liability through calculations we perform for the determination of our current tax liability, together with assessing temporary differences resulting from the different treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are recorded in our balance sheets. Our management then assesses the likelihood that deferred tax assets will be recovered in future periods through future operating results. To the extent that we cannot conclude that it is more likely than not that the benefit of such assets will be realized, we establish a valuation allowance to adjust the net carrying value of such assets. The carrying value of our net deferred tax assets assumes that we will be able to generate sufficient future taxable income, based on management’s estimates and assumptions. These estimates and assumptions take into consideration future taxable income and ongoing feasible tax strategies in determining recoverability of such assets. Our valuation allowance is subject to significant change based on management’s estimates of future profitability and the ultimate realization of the deferred tax assets. The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets.

Results of Operations

Quarters Ended September 30, 2012 and September 30, 2011

Revenues:   Revenues were $5,403,537 for the quarter ended September 30, 2012, as compared to $5,100,649 for the quarter ended September 30, 2011, an increase of $302,888. The increase was primarily due to an increase in pharmaceutical revenues of $619,909 offset by a decrease in ResponseDX^® revenue of $317,021. ResponseDX^® revenue accounted for 56.0% of total revenue for the quarter ended September 30, 2012 compared to 65.5% for the quarter ended September 30, 2011.  For the quarter ended September 30, 2012, our two most significant pharmaceutical customers accounted for approximately 31% of our revenue, as compared to approximately 29% of our revenue for the quarter ended September 30, 2011.

Cost of Revenues:   Cost of revenue for the quarter ended September 30, 2012 was $2,768,894 as compared to $2,538,176 for the quarter ended September 30, 2011, an increase of $230,718 or 9.1%.  This increase resulted primarily from increases in lab supplies and reagent costs of $134,842, fees to Hitachi and Shanghai Bio of $101,193, personnel costs of $145,895, and rent of $51,081 offset in part by decreases in legal fees of $89,389, royalties of $36,830, consulting of $91,822, and travel expense of $16,888. Cost of revenues as a percentage of revenues was 51.2% for the quarter ended September 30, 2012, as compared to 49.8% for the quarter ended September 30, 2011, an increase of 1.4%.

26

Research and Development Expenses:   Research and development expenses were $426,105 for the quarter ended September 30, 2012, as compared to $452,734 for the quarter ended September 30, 2011, a decrease of $26,629 or 5.9%.  This decrease resulted primarily from a decrease in lab supplies of $114,773, offset by an increase in personnel costs of $98,306. We expect research and development expenses to increase as we continue work to develop additional aspects of our technology and to study diagnostic indicators for various forms of cancer.

General and Administrative Expenses:  General and administrative expenses were $2,407,544 for the quarter ended September 30, 2012, as compared to $2,268,517 for the quarter ended September 30, 2011, an increase of $139,027 or 6.1%.  This increase resulted primarily from increases in personnel costs of $121,562, legal fees of $41,467, bad debt expense of $428,965, and audit fees of $99,453, offset in part by decreases in travel of $100,738, billing fees of $123,881, foreign currency loss of $71,626, and a 2011 asset impairment charge of $157,241.

Sales and Marketing Expenses:   Sales and marketing expenses were $1,195,988 for the quarter ended September 30, 2012, as compared to $1,251,054 for the quarter ended September 30, 2011, a decrease of $55,066 or 4.4%.  The decrease primarily resulted from decreased sales activities for ResponseDX^® in the form of lower personnel costs of $64,483.  We expect that sales and marketing costs will increase as we expand our sales and marketing activities in order to gain clinical acceptance of our ResponseDX ^® assays.

Income Taxes:   As of September 30, 2012 and 2011, since we have incurred substantial losses and have generated no taxable income, a full valuation allowance has been recorded for the deferred tax assets since we do not believe the recoverability of the deferred income tax assets in the near future is more likely than not.

Nine Months Ended September 30, 2012 and September 30, 2011

Revenues:  Revenues were $13,220,188 for the nine months ended September 30, 2012, as compared to $17,730,785 for the nine months ended September 30, 2011, a decrease of $4,510,597.  This decrease was primarily due to a decrease in pharmaceutical revenue of $3,894,438 resulting from decreased sample volume from one of our largest customers during the first half of 2012 relative to 2011, and a decrease from prior year in ResponseDX^® revenues of $616,159.  ResponseDX^® revenue accounted for 67% of total revenue for the nine months ended September 30, 2012 compared to 53% for the nine months ended September 30, 2011.For the nine months ended September 30, 2012, our two most significant pharmaceutical customers accounted for approximately 19.8% of our revenue, as compared to approximately 39.7% of our revenue for the nine months ended September 30, 2011.

Cost of Revenues:   Cost of revenues for the nine months ended September 30, 2012 were $7,895,870 as compared to $8,040,003 for the nine months ended September 30, 2011, a decrease of $144,133 or 1.8%.  This decrease resulted primarily from decreases in royalties of $327,679, fees to third party processors of $188,616, travel of $57,201, consulting of $56,202 and legal services of $296,234, offset in part by an increase in lab supplies and reagent costs of $70,171, personnel costs of $469,570, depreciation and amortization of $75,960, and facility expense of $167,029.  Cost of revenues as a percentage of revenues was 59.7% for the nine months ended September 30, 2012, as compared to 45.3% for the nine months ended September 30, 2011, an increase of 14.4%.

Research and Development Expenses:   Research and development expenses were $1,695,851 for the nine months ended September 30, 2012, as compared to $838,622 for the nine months ended September 30, 2011, an increase of $857,229 or 102%.  This increase resulted primarily from increases in lab supplies and reagent costs of $409,694, personnel costs of $368,172, consulting costs of $40,448, and legal costs of $189,523. We expect research and development expenses to increase as we continue to work to develop additional aspects of our technology and to study diagnostic indicators for various forms of cancer.

General and Administrative Expenses:  General and administrative expenses were $6,686,559 for the nine months ended September 30, 2012, as compared to $6,493,079 for the nine months ended September 30, 2011, an increase of $193,480 or 3.0%.  This increase resulted primarily from increases in personnel costs of $207,566, audit fees of $101,901, legal costs of $59,178, business consulting $62,155, and bad debt expense of $436,299, offset by decreases in travel of $116,623, business taxes of $217,335, billing services of $281,119 and a 2011 asset impairment charge of $157,241.

Sales and Marketing Expenses:   Sales and marketing expenses were $4,145,115 for the nine months ended September 30, 2012, as compared to $4,107,639 for the nine months ended September 30, 2011, an increase of $37,476 or 0.9%.  This increase primarily resulted from increased sales and marketing activities for ResponseDX^®, which included increases in business travel of $46,988 and business consulting of $73,351, offset by decreases in personnel costs of $71,321. We expect that sales and marketing costs will continue to increase as we expand our sales and marketing activities in order to gain clinical acceptance of our ResponseDX^® assays.

Income Taxes:   As of September 30, 2012 and 2011, since we have incurred substantial losses and have generated no taxable income, a full valuation allowance has been recorded for the deferred tax assets since we do not believe the recoverability of the deferred income tax assets in the near future is more likely than not.

27

Liquidity and Capital Resources

We incurred net losses of $1,415,540 and $1,415,488 during the three months ended September 30, 2011 and 2012, respectively. Since our inception in September 1999, we have incurred cumulative losses and as of September 30, 2012, we had an accumulated deficit of $56,789,324. We have not yet achieved profitability and anticipate that we will likely incur additional losses for the next year. We cannot provide assurance as to when we will achieve profitability. We expect that our cash and cash equivalents will continue to be used to fund our selling and marketing activities primarily related to our ResponseDX^® tests, research and development, and general corporate purposes. As a result, we will need to generate significant revenues to achieve profitability or raise additional financing in the future, as needed. However, there can be no assurance that any additional financing will be available on acceptable terms, if at all.

As of September 30, 2012, we had $10,839,201 in cash and cash equivalents and working capital of $10,266,072. In the nine months ended September 30, 2012, we used cash flows in operating activities of $6,489,572. As such, we believe we have adequate resources to meet our operating commitments for at least the next twelve months.

Sales of Common Stock

Under the Company’s Articles of Incorporation, the Company has one class of common stock and its holders have no preemptive, subscription, redemption or conversion rights.  As described below and in Note 11 in the notes to Consolidated Financial Statements, the Company sold shares of its common stock during 2011 and during the first and third quarters of 2012.  In connection with certain of these offerings, the Company entered into registration rights agreements with the purchasers of the common shares which give such purchasers certain registration rights.

May 2011 Registered Offering of Common Stock

On May 6, 2011, the Company issued 1,175,512 shares of its common stock at a price of $1.99 per share in a registered direct public offering to certain institutional investors and received net proceeds of approximately $2.2 million from the sales, after deducting its estimated offering expenses. The securities issued with this financing were registered under the Securities Act of 1933, as amended. The shares were issued pursuant to a prospectus supplement dated May 4, 2011 and an accompanying prospectus dated January 6, 2011, pursuant to the Company’s existing effective shelf registration statement on Form S-3 (File No. 333-171266), which was filed with the SEC on December 17, 2010 and declared effective by the SEC on January 6, 2011.

Common stock classified outside of stockholders’ equity (deficit)

March 2010 Private Placement

On March 5, 2010, we entered into a purchase agreement with certain affiliates of and funds managed by Lansdowne (“Lansdowne”), Greenway Capital Partners and Paragon Associates for the private placement of 3,005,349 newly-issued shares of our common stock at a per share price of $1.31.  The closing of the sale of the shares occurred on March 5, 2010.  In connection with the acquisition of the shares, the purchasers were granted certain preemptive rights permitting them to maintain their percentage ownership interests in connection with future issuances of our capital stock, subject to various exceptions and limitations.  Lansdowne participated in the private placement by electing to exercise the preemptive rights granted to it pursuant to the purchase agreement by and between the Company and Lansdowne, dated July 22, 2009. Net proceeds received from this financing were approximately $3,879,403.

In connection with the private placement, we also entered into a registration rights agreement, dated March 5, 2010, with the purchasers pursuant to which it agreed to file, within 45 days of the closing of the private placement, a registration statement with the SEC to register the shares for resale, which registration statement was required to become effective within 120 days following the closing.  We also granted certain "piggyback" registration rights to the purchasers which are triggered if we propose to file a registration statement for its own account or the account of one or more shareholders until the earlier of the sale of all of the shares or the shares becoming eligible for sale under Rule 144(b)(1) without restriction.

Pursuant to the registration rights agreement dated March 5, 2010, the Company filed a registration statement with the SEC to register the 3,005,349 shares sold to Lansdowne, Greenway and Paragon for resale, which became effective on May 19, 2010 and which registration statement remained effective as of September 30, 2012.

28

Under the registration rights agreements dated March 5, 2010, the Company is obligated to use commercially reasonable efforts to (i) cause the registration statement described above to remain continuously effective and (ii) to maintain the listing of Company’s common stock on NASDAQ or other exchanges, as defined, for a period that will terminate on the earlier of March 5, 2013 or the date on which the purchasers have sold all shares of common stock.  The Company is also required to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In the event the Company fails to satisfy its obligations under the registration rights agreements, the Company would be in breach of said agreements, in which event, the purchasers would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. These registration rights agreements do not provide an explicitly stated or defined penalty due upon a breach.  Because (i) the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements and (ii) complying with all filing requirements under the Exchange Act as described above is not solely within the Company’s control, the Company  is required to present the investment of $3,879,403 in the Company’s common stock as common stock outside of stockholders’ equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities .

On January 18, 2012, the restrictions were removed on 3,658,676 shares purchased by Lansdowne, including all of the shares purchased by Lansdowne in the March 2010 private placement, and these shares were reclassified to common stock from common stock classified outside of equity (deficit).

February 2012 Private Placement

On February 2, 2012, the Company entered into purchase agreements with various investors (collectively, the “February Investors”) for the private placement of an aggregate of 5,257,267 newly-issued shares of the Company’s common stock (the “February Shares”) at a purchase price of $1.50 per share (the “February 2012 Private Placement”). Net cash proceeds raised in the February 2012 Private Placement were approximately $7,822,000. The February Investors participating in the February 2012 Private Placement were various institutions and all officers and directors of the Company. The final closing of the February 2012 Private Placement (the “February Closing”) occurred on February 2, 2012.

In connection with the February 2012 Private Placement, the Company also entered into registration rights agreements, each dated February 2, 2012, with the February Investors pursuant to which the Company agreed to file, within 90 days of the February Closing, a registration statement with the SEC to register the February Shares for resale, which registration statement was required to become effective within 180 days following the February Closing. The Company also granted the February Investors certain “piggyback” registration rights, which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more shareholders until the earlier of the sale of all of the February Shares or the February Shares becoming eligible for sale under Rule 144(b)(1) without restriction.

Pursuant to the registration rights agreements dated February 2, 2012, the Company filed a registration statement with the SEC on April 30, 2012, to register the February Shares for resale. This registration statement became effective on May 17, 2012 and remained effective as of September 30, 2012.

Under the registration rights agreements with the February Investors, the Company is obligated to use commercially reasonable efforts to (i) cause the registration statements described above to remain continuously effective and (ii) to maintain the listing of Company’s common stock on NASDAQ or other exchanges, as defined, for a period that will terminate on the earlier of February 2, 2013, or the date on which the February Investors have sold all shares of common stock.  The Company is also required to file with the SEC in a timely manner all reports and other documents required of the Company required of the Company under the Exchange Act.  In the event the Company fails to satisfy its obligations under the registration rights agreements, the Company would be in breach of said agreements, in which event, the February Investors would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. These registration rights agreements do not provide an explicitly stated or defined penalty due upon a breach.  Because (i) the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements and (ii) complying with all filing requirements under the Exchange Act as described above is not solely within the Company’s control, the Company  is required to present the investment of approximately $7,884,400 in the Company’s common stock as common stock outside of stockholders’ equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities.

29

September 2012 Private Placement

On September 13, 2012, the Company entered into a purchase agreement (the “Purchase Agreement”) with Glaxo Group Limited, an affiliate of GSK (the “GSK Investor”) and two existing investors, Swiftcurrent Partners, L.P. and Swiftcurrent Offshore, Ltd. (collectively with the GSK Investor, the “September Investors”) for the private placement of an aggregate of 8,000,000 newly-issued shares of the Company’s common stock (the “September Shares”) at a purchase price of $1.10 per share (the “September 2012 Private Placement”). The Company raised gross cash proceeds of $8,800,000 in the September 2012 Private Placement which closed (the “Closing”) on September 13, 2012.

Pursuant to the Purchase Agreement, for so long as the GSK Investor or its affiliates own at least 50% of the September Shares it purchased pursuant to the Purchase Agreement, the GSK Investor has the right to designate one non-voting board observer (the "Board Observer"). The Board Observer, if appointed, has the right to attend all meetings of the Board of Directors of the Company and to receive all board meeting materials, subject to certain restrictions set forth in the Purchase Agreement. As of the date hereof, the GSK Investor has not exercised its right to designate the Board Observer.

In connection with the September 2012 Private Placement, the Company also entered into a registration rights agreement, dated September 13, 2012 (the “September Registration Rights Agreement”), with the September Investors pursuant to which the Company agreed to file, within 45 days of the Closing, a registration statement with the SEC to register the September Shares for resale, which registration statement is required to become effective within 180 days following the Closing. The Company also granted the September Investors certain “piggyback” registration rights, which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more stockholders until the earlier of the sale of all of the September Shares or the September Shares becoming eligible for sale under Rule 144(b)(1) without restriction.

Under the September Registration Rights Agreement, the Company is obligated to use commercially reasonable efforts to cause a registration statement to become effective and to remain continuously effective and to maintain the listing of the covered common stock on NASDAQ or other exchanges, as defined, for a period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration Statement as amended from time to time, have been sold, (ii) the date on which there are no longer any Registrable Securities outstanding or (iii) three years from the date of filing of such Registration Statement (the “ Effectiveness Period ”) and advise each September Investor in writing when the Effectiveness Period has expired. “Registrable Securities” means (i) the September Shares and (ii) shares of capital stock or any other securities issued or issuable with respect to or in exchange for the September Shares; provided, that, a security shall cease to be a Registrable Security with respect to a September Investor upon (A) sale by such September Investor pursuant to a registration statement or Rule 144 under the 1933 Act, or (B) such security becoming eligible for sale by such September Investor without restriction pursuant to Rule 144(b)(1).   In the event the Company fails to satisfy its obligations under the September Registration Rights Agreement, the Company would be in breach of such agreement, in which event, the September Investors would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. The September Registration Rights Agreement does not provide an explicitly stated or defined penalty due upon a breach.  Because the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements, the Company  is required to present the investment of approximately $8,800,000 in the Company’s common stock as common stock outside of stockholders’ equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities.

Pursuant to the September Registration Rights Agreement, the Company filed a registration statement with the SEC on October 26, 2012, to register the September Shares for resale. This registration statement became effective on November 13, 2012.

30

Comparison of Cash Flows for the Nine Months Ended September 30, 2012 and 2011

As of September 30, 2012, we had $10,839,201 in cash and cash equivalents, working capital of $10,226,072 and an accumulated deficit of $56,789,324. As of September 30, 2011, we had $2,532,009 in cash and cash equivalents, working capital of $4,771,573 and an accumulated deficit of $45,576,937.

Cash flows provided by operating activities

During the nine months ended September 30, 2012, the Company used cash flows in operating activities of $6,489,572 compared to $6,353,530 used in the six months ended June 30, 2012 and the $3,316,714 used in the nine months ended September 30, 2011.  The primary reason for the increase in cash used in operating activities of $3,172,858 was the increase in net loss the Company incurred for the nine month period ended September 30, 2012 compared to the nine month period ended September 30, 2011. The net loss for the Company was primarily driven by a decrease in pharmaceutical revenue of $3,894,438.

Cash flows used in investing activities

Net cash used in investing activities was $726,754 for the nine months ended September 30, 2012 compared to $357,154 for the nine months ended September 30, 2011.  The increase was primarily attributable to the purchase of a Laboratory Information Management (“LIM”) system and the associated implementation costs for the period.

Cash flows used in financing activities

Cash flows from financing activities for the nine months ended September 30, 2012 provided net cash of $16,355,626 relating to the sale of common stock.  Cash flows from financing activities for the nine months ended September 30, 2011 provided net cash of $2,168,905 relating to the sale of common stock and a capital contribution.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

31

ITEM 3. Qualitative and Quantitative Disclosures about Market Risk.

Not applicable.

ITEM 4. Controls and Procedures.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Under the supervision, and with the participation of our management, including the Principal Executive Officer and Principal Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15 and 15d-15 as of the end of the period covered by this report. Based on that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that these disclosure controls and procedures were effective such that the material information required to be filed in this report is recorded, processed, summarized and reported within the required time periods specified in SEC rules and forms. This conclusion was based on the fact that the business operations to date have been limited and our Principal Executive Officer and Principal Financial Officer have had complete access to all records and financial information and have availed themselves of such access to ensure full disclosure.

It should be noted that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. As a result, there can be no assurance that a control system will succeed in preventing all possible instances of error and fraud. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, and the conclusions of our Principal Executive Officer and the Principal Financial Officer are made at the “reasonable assurance” level.

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings.

The Company is, from time to time, involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. These matters are not expected to have a material adverse effect upon the Company’s financial condition.

ITEM 1A. Risk Factors

Not applicable.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

32

ITEM 3. Defaults Upon Senior Securities.

None.

ITEM 4. Mine Safety Disclosures

Not applicable.

ITEM 5. Other Information.

None.

ITEM 6. Exhibits.

31.1	Certification of Principal Executive Officer Pursuant to Section 302.
31.2	Certification of Principal Financial Officer Pursuant to Section 302.
32	Section 906 certification of periodic financial report by Chief Executive Officer and Chief Financial Officer.

33

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	RESPONSE GENETICS, INC.
DATE: November 14, 2012	By:	/s/ Thomas A. Bologna
		Thomas A. Bologna
		Chief Executive Officer (Principal Executive Officer)
DATE: November 14, 2012	By:	/s/ Kevin R. Harris
		Kevin R. Harris
		Interim Chief Financial Officer (Principal Financial Officer)

34

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Thomas A. Bologna , certify that:

1. I have reviewed this quarterly report on Form 10-Q of Response Genetics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2012

/s/ Thomas A. Bologna

Thomas A. Bologna

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Kevin R. Harris, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Response Genetics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2012

/s/ Kevin R. Harris

Kevin R. Harris

Interim Chief Financial Officer

EX-32

Exhibit 32

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Response Genetics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the period ended September 30, 2012 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2012	/s/ Thomas A. Bologna
	Chief Executive Officer
Dated: November 14, 2012	/s/ Kevin R. Harris
	Interim Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification “accompanies” the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

XML

Loss Per Share (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares excluded from the calculation of diluted loss per share	1,900,675	1,996,931	1,900,675	1,996,931
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of outstanding and exercisable warrants expired			100,000

XML

Subsequent Events (Details) (Subsequent Event [Member])	Oct. 26, 2012
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares registered for resale	8,800,000

XML

Stock Option Plans (Schedule of Awards to Mr. Bologna) (Details) (USD $)	9 Months Ended	12 Months Ended	1 Months Ended	9 Months Ended	1 Months Ended		9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Dec. 21, 2011 Thomos Bologna [Member] Restricted Stock Units (RSUs) [Member]	Sep. 30, 2012 Thomos Bologna [Member] Restricted Stock Units (RSUs) [Member]	Dec. 21, 2011 Thomos Bologna [Member] Stock Options [Member]	Dec. 21, 2011 Thomos Bologna [Member] Stock Options [Member] Period One [Member]	Sep. 30, 2012 Thomos Bologna [Member] Stock Options [Member] Period One [Member]	Sep. 30, 2012 Thomos Bologna [Member] Stock Options [Member] Period Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date				Dec. 21, 2011			Dec. 31, 2011	Dec. 21, 2011
Number of Awards			270,000	270,000
Stock option granted, number of common stock shares	914,200					600,000	600,000	300,000
Intrinsic Value				$ 13,500
Intrinsic Value	$ 2,649						$ 30,000	$ 15,000
Exercise Price
Stock option granted, exercise price	$ 1.47				$ 1.2		$ 1.2	$ 1.2
Options Exercisable
Options Exercisable	765,672						150,000	300,000
Remaining Contractual Term	9 years 3 months 15 days	7 years 4 months 24 days		9 years 2 months 12 days			9 years 2 months 12 days	9 years 2 months 12 days

XML

Stock Option Plans (Schedule of Options Outstanding) (Details) (USD $)	9 Months Ended
	Sep. 30, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding Number of Options	1,900,675
Options Outstanding WA Remaining Contractual Term	8 years 3 months 22 days
Options Exercisable Number of Options	765,672
Options Exercisable WA Remaining Contractual Term	6 years 9 months 11 days
$ 1.16 to 1.17 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, minimum	1.16
Exercise Price, maximum	1.17
Options Outstanding Number of Options	490,700
Options Outstanding WA Remaining Contractual Term	9 years 9 months 29 days
Options Exercisable Number of Options	20,459
Options Exercisable WA Remaining Contractual Term	9 years 9 months 29 days
$ 1.32 to 1.35 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, minimum	1.32
Exercise Price, maximum	1.35
Options Outstanding Number of Options	196,316
Options Outstanding WA Remaining Contractual Term	7 years 1 month 2 days
Options Exercisable Number of Options	141,233
Options Exercisable WA Remaining Contractual Term	6 years 8 months 16 days
$ 1.65 to 1.67 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, minimum	1.65
Exercise Price, maximum	1.67
Options Outstanding Number of Options	327,750
Options Outstanding WA Remaining Contractual Term	9 years 2 months 19 days
Options Exercisable Number of Options	5,210
Options Exercisable WA Remaining Contractual Term	9 years 7 months 28 days
$ 1.86 to 2.06 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, minimum	1.86
Exercise Price, maximum	2.06
Options Outstanding Number of Options	220,000
Options Outstanding WA Remaining Contractual Term	9 years 5 months 27 days
Options Exercisable Number of Options	16,044
Options Exercisable WA Remaining Contractual Term	9 years 5 months 23 days
$ 2.21 to 2.35 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, minimum	2.21
Exercise Price, maximum	2.35
Options Outstanding Number of Options	285,500
Options Outstanding WA Remaining Contractual Term	8 years 1 month 6 days
Options Exercisable Number of Options	235,500
Options Exercisable WA Remaining Contractual Term	8 years 2 months 16 days
$ 2.71 to 3.24 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, minimum	2.71
Exercise Price, maximum	3.24
Options Outstanding Number of Options	172,409
Options Outstanding WA Remaining Contractual Term	6 years 9 months 29 days
Options Exercisable Number of Options	139,226
Options Exercisable WA Remaining Contractual Term	6 years 7 months 6 days
$ 3.80 to 4.29 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, minimum	3.8
Exercise Price, maximum	4.29
Options Outstanding Number of Options	23,000
Options Outstanding WA Remaining Contractual Term	5 years 2 months 12 days
Options Exercisable Number of Options	23,000
Options Exercisable WA Remaining Contractual Term	5 years 2 months 12 days
$ 7.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, minimum	7.0
Exercise Price, maximum	7.0
Options Outstanding Number of Options	185,000
Options Outstanding WA Remaining Contractual Term	4 years 8 months 9 days
Options Exercisable Number of Options	185,000
Options Exercisable WA Remaining Contractual Term	4 years 8 months 9 days

XML

Summary of Significant Accounting Policies (Schedule of Customers that Account for Greater than 10 Percent of Accounts Receivable) (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivable Balance	$ 4,383,958	$ 4,047,059
Glaxo, Smith, Kline [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivable Balance	275,553	476,526
Percent of Total Receivables	5.00%	10.00%
Glaxo Smith Kline Biologicals [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivable Balance	276,206	1,079,570
Percent of Total Receivables	5.00%	22.00%
Medicare [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivable Balance	$ 774,237	$ 506,308
Percent of Total Receivables	15.00%	10.00%

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2012

Segment Information [Abstract]

Schedule of Financial Information by Geographic Area

	Three Months Ended September 30,				Nine Months Ended September 30,
Net Revenue:	2011		2012		2011		2012
	(Unaudited)				(Unaudited)
United States	$	3,833,037	$	3,890,842	$	12,740,800	$	10,310,236
Europe		1,109,112		893,060		4,186,385		1,672,387
Japan		158,500		619,635		803,600		1,237,565
	$	5,100,649	$	5,403,537	$	17,730,785	$	13,220,188

Long-lived assets:	December 31, 2011		September 30, 2012
			(Unaudited)
United States	$	1,112,102	$	1,490,572

XML

Income Taxes (Details)	9 Months Ended
	Sep. 30, 2012
Income Taxes [Abstract]
Years subject to tax examination	from 2002 through 2011

XML

License and Collaborative Agreements (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended			1 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		1 Months Ended		12 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		0 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2012 Licensing Agreements [Member] University of Southern California [Member]	Sep. 30, 2011 Licensing Agreements [Member] University of Southern California [Member]	Sep. 30, 2012 Licensing Agreements [Member] University of Southern California [Member]	Sep. 30, 2011 Licensing Agreements [Member] University of Southern California [Member]	Sep. 30, 2012 Licensing Agreements [Member] Roche Molecular Systems [Member]	Sep. 30, 2011 Licensing Agreements [Member] Roche Molecular Systems [Member]	Sep. 30, 2012 Licensing Agreements [Member] Roche Molecular Systems [Member]	Sep. 30, 2011 Licensing Agreements [Member] Roche Molecular Systems [Member]	Sep. 30, 2012 Licensing Agreements [Member] Glaxo, Smith, Kline [Member]	Jan. 31, 2011 Service Agreements [Member] Taiho Pharmaceutical Co., Ltd. [Member]	Sep. 30, 2012 Service Agreements [Member] Taiho Pharmaceutical Co., Ltd. [Member]	Sep. 30, 2011 Service Agreements [Member] Taiho Pharmaceutical Co., Ltd. [Member]	Sep. 30, 2012 Service Agreements [Member] Taiho Pharmaceutical Co., Ltd. [Member]	Sep. 30, 2011 Service Agreements [Member] Taiho Pharmaceutical Co., Ltd. [Member]	Sep. 30, 2012 Service Agreements [Member] GlaxoSmithKline, LLC [Member]	Sep. 30, 2011 Service Agreements [Member] GlaxoSmithKline, LLC [Member]	Sep. 30, 2012 Service Agreements [Member] GlaxoSmithKline, LLC [Member]	Sep. 30, 2011 Service Agreements [Member] GlaxoSmithKline, LLC [Member]	Jan. 31, 2010 Service Agreements [Member] GlaxoSmithKline, LLC [Member] Up-front Payment Arrangement [Member]	Jan. 31, 2006 Service Agreements [Member] GlaxoSmithKline, LLC [Member] Up-front Payment Arrangement [Member]	Dec. 31, 2008 Amended and Restated Service Agreement [Member] GlaxoSmithKline, LLC [Member]	Sep. 30, 2012 Amended and Restated Service Agreement [Member] GSK Bio [Member]	Sep. 30, 2011 Amended and Restated Service Agreement [Member] GSK Bio [Member]	Sep. 30, 2012 Amended and Restated Service Agreement [Member] GSK Bio [Member]	Sep. 30, 2011 Amended and Restated Service Agreement [Member] GSK Bio [Member]	Sep. 30, 2012 Collaborative Arrangement [Member] Shanghai BioChip Company, Ltd. [Member]	Sep. 30, 2011 Collaborative Arrangement [Member] Shanghai BioChip Company, Ltd. [Member]	Sep. 30, 2012 Collaborative Arrangement [Member] Shanghai BioChip Company, Ltd. [Member]	Sep. 30, 2011 Collaborative Arrangement [Member] Shanghai BioChip Company, Ltd. [Member]	Mar. 05, 2007 Collaborative Arrangement [Member] Hitachi Chemical Co., Ltd. [Member]	Sep. 30, 2012 Collaborative Arrangement [Member] Hitachi Chemical Co., Ltd. [Member]	Sep. 30, 2011 Collaborative Arrangement [Member] Hitachi Chemical Co., Ltd. [Member]	Sep. 30, 2012 Collaborative Arrangement [Member] Hitachi Chemical Co., Ltd. [Member]	Sep. 30, 2011 Collaborative Arrangement [Member] Hitachi Chemical Co., Ltd. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty expense included in cost of revenue	$ 98,740	$ 123,873	$ 231,180	$ 382,685	$ 105,170	$ 116,867	$ 249,057	$ 425,232
Collaborative agreement, extension period										3 years											2 years
Revenue recognized											585,625	158,500	1,122,425	536,800	777,571	356,594	1,000,147	2,878,860				886,945	1,109,112	1,619,372	4,186,385	0	84,275		234,512		291,728	106,260	526,057	481,951
Revenue deferred																			1,300,000	2,000,000
Milestone payment received									$ 500,000
Collaborative agreement, optional additional period																					1 year							3 years					1 year
Collaborative agreement, term																														5 years
Collaborative agreement, termination notice period																												90 days

XML

Property and Equipment and Intangible Assets (Schedule of Future Minimum Lease Payments under Capital Leases) (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Property and Equipment and Intangible Assets [Abstract]
2012	$ 44,907
2013	175,548
2014	87,119
Total minimum lease payments	307,574
Less amount represented by interest	(26,732)
Less current portion	(158,821)	(149,253)
Capital lease obligation, net of current portion	$ 122,021	$ 240,928

XML

Sale of Common Stock (Details) (USD $)	1 Months Ended		9 Months Ended				1 Months Ended			1 Months Ended
	Feb. 29, 2012	May 31, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	May 06, 2011	Sep. 30, 2012 Private Placement [Member]	Feb. 29, 2012 Private Placement [Member]	Feb. 02, 2012 Private Placement [Member]	Jan. 18, 2012 Lansdowne Partners Limited Partnership, Greenway Capital Partners and Paragon Associates [Member]	Mar. 31, 2010 Lansdowne Partners Limited Partnership, Greenway Capital Partners and Paragon Associates [Member]	Feb. 02, 2012 Lansdowne Partners Limited Partnership, Greenway Capital Partners and Paragon Associates [Member]	Mar. 05, 2010 Lansdowne Partners Limited Partnership, Greenway Capital Partners and Paragon Associates [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock shares issued		1,175,512					8,000,000	5,257,267			3,005,349
Common stock issued, price per share						$ 1.99	$ 1.1		$ 1.5				$ 1.31
Net proceeds from issuance of common stock			$ 16,464,965	$ 2,179,535			$ 8,800,000
Net proceeds from issuance of shares in Private Placement	7,822,000										3,879,403
Registration statement filing period after closing of Private Placement							45 days					90 days	45 days
Registration statement effective period after closing of Private Placement							180 days					180 days	120 days
Number of shares included in a registration statement to be registered with the SEC													3,005,349
Common stock classified outside of stockholders' equity (deficit)			$ 19,575,724		$ 7,854,682		$ 8,800,000					$ 7,884,400	$ 3,879,403
Common stock purchased										3,658,676
Percentage of shares purchased required to be held for board observer designation right							50.00%

XML

Stock Option Plans (Schedule of Stock-Based Compensation Included in Results of Operations) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Totals	$ 162,513	$ 206,719	$ 683,897	$ 703,771
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	12,603	61,395	46,839	208,672
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	17,167	10,951	29,591	37,221
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	11,277	5,521	39,337	18,765
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 121,466	$ 128,852	$ 568,130	$ 439,113

XML

Loss Per Share

9 Months Ended

Sep. 30, 2012

Loss Per Share [Abstract]

Loss Per Share

4. Loss Per Share

The Company calculates net loss per share in accordance with ASC 260, Earnings Per Share. Under the provisions of ASC 260, basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents then outstanding. Common stock equivalents consist of shares of common stock issuable upon the exercise of stock options and warrants.

The following table sets forth the computation for basic and diluted loss per share:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2012			2011			2012
	( Unaudited )						( Unaudited )
Numerator:
Net loss	$	(1,415,540	)	$	(1,415,488	)	$	(1,759,775	)	$	(7,269,739	)
Numerator for basic and diluted earnings per share	$	(1,415,540	)	$	(1,415,488	)	$	(1,759,775	)	$	(7,269,739	)
Denominator:
Denominator for basic and diluted earnings per share - weighted-average shares		19,537,232			26,362,842			18,979,010			24,709,185
Basic and diluted loss per share	$	(0.07	)	$	(0.05	)	$	(0.09	)	$	(0.29	)

Outstanding stock options and warrants to purchase 1,996,931 and 1,900,675 shares for the periods ended September 30, 2011 and 2012, respectively, were excluded from the calculation of diluted loss per share as their effect would have been antidilutive. All of the 100,000 warrants that were outstanding and exercisable had expired by September 30, 2012.

XML

Stock Option Plans (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended			1 Months Ended	3 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended	1 Months Ended		9 Months Ended	1 Months Ended	9 Months Ended					1 Months Ended					9 Months Ended			9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 21, 2011 Thomos Bologna [Member] Stock Options [Member]	Sep. 30, 2012 Thomos Bologna [Member] Stock Options [Member]	Sep. 30, 2012 Thomos Bologna [Member] Stock Options [Member]	Dec. 21, 2011 Thomos Bologna [Member] Stock Options [Member] Period One [Member]	Sep. 30, 2012 Thomos Bologna [Member] Stock Options [Member] Period One [Member]	Dec. 21, 2011 Thomos Bologna [Member] Stock Options [Member] Period Four [Member]	Dec. 31, 2011 Thomos Bologna [Member] Stock Options [Member] Period Four [Member]	Sep. 30, 2011 Thomos Bologna [Member] Stock Options [Member] Period Four [Member]	Dec. 21, 2011 Thomos Bologna [Member] Restricted Stock Units (RSUs) [Member]	Sep. 30, 2012 Thomos Bologna [Member] Restricted Stock Units (RSUs) [Member]	Sep. 30, 2012 Minimum [Member] Thomos Bologna [Member] Stock Options [Member]	Sep. 30, 2012 Minimum [Member] Thomos Bologna [Member] Restricted Stock Units (RSUs) [Member]	Sep. 30, 2012 Maximum [Member] Thomos Bologna [Member] Stock Options [Member]	Mar. 31, 2000 Stock Option Plan 2000 [Member]	Mar. 31, 2000 Other Stock Plans [Member]	Jan. 31, 2011 2006 Stock Plan [Member]	Jan. 31, 2010 2006 Stock Plan [Member]	Jan. 31, 2009 2006 Stock Plan [Member]	Jan. 31, 2008 2006 Stock Plan [Member]	Sep. 30, 2012 2006 Stock Plan [Member]	Jan. 31, 2012 2006 Stock Plan [Member]	Oct. 26, 2006 2006 Stock Plan [Member]	Sep. 30, 2012 Employee Stock Option [Member]	Sep. 30, 2012 Non Employee Stock Options [Member] Minimum [Member]	Sep. 30, 2012 Non Employee Stock Options [Member] Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized																			1,600,000							3,160,000	2,160,000
Options outstanding	1,900,675		1,900,675		1,870,846
Number of consultants who were granted stock options																				2
Stock option granted, number of common stock shares			914,200						600,000	600,000	300,000	300,000								16,000
Increase in the number of shares available for issuance																					200,000	200,000	200,000	200,000	200,000
Increase in the number of shares available for issuance, percent of stock outstanding																									5.00%
Number of options available to grant																									1,059,325
Options expiration period																												10 years
Options vesting period									36 months							18 months		36 months											2 years	3 years
Options outstanding, weighted average exercise price	$ 2.29		$ 2.29		$ 3.67
Non-vested stock options outstanding	1,135,003		1,135,003
Non-vested stock options outstanding, Weighted average grant date fair value	$ 1.05		$ 1.05
Unrecognized compensation costs related to non-vested stock options	$ 886,077		$ 886,077
Unrecognized compensation costs related to non-vested stock options, recognition period			2 years 5 months 19 days
Stock options granted, average fair value			$ 1.47	$ 2.27
Average closing price of common stock										$ 1.2						$ 1.8	$ 2.4
Number of days, for calculating average closing price of common stock						30 days								30 days
Number of restricted common stock granted														270,000	270,000
Stock option granted, exercise price			$ 1.47			$ 1.2				$ 1.2
Share-based compensation	$ 162,513	$ 206,719	$ 683,897	$ 703,771			$ 104,468	$ 440,133					$ 129,000

XML

Summary of Significant Accounting Policies (Schedule of ResponseDX Accounts Receivable) (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts	$ (864,419)	$ (838,750)
Total	4,383,958	4,047,059
Medicare [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total	774,237	506,308
ResponseDX [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	3,824,731	3,183,972
Allowance for doubtful accounts	(864,419)	(838,750)
Total	2,960,312	2,345,222
ResponseDX [Member] | Medicare [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	774,237	506,308
ResponseDX [Member] | Private Client [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	3,050,494	2,634,838
ResponseDX [Member] | Other Payor [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable		$ 42,826

XML

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Significant Accounting Policies [Line Items]
Receivable Balance	$ 4,383,958		$ 4,383,958		$ 4,047,059
Bad debt expense			897,182	460,883
Amortization period of software development costs			3 years
Line of credit agreement date			Jul. 04, 2011
Line of credit, maximum borrowing capacity	2,000,000		2,000,000
Line of credit, borrowing base percentage of pharmaceutical accounts receivable	80.00%		80.00%
Line of credit borrowing base, age of pharmaceutical accounts receivable	90 days		90 days
Line of credit, interest above prime rate	1.00%		1.00%
Line of credit, interest charged			5.00%
Line of credit, amount drawn	1,000,000		1,000,000		1,000,000
Required minimum bank balance	4,000,000		4,000,000
Bank line of credit, over-advance amount required to be repaid	298,000		298,000
Advertising costs	655	16,985	13,626	83,462
Insurance coverage per depositor at each financial institution	250,000		250,000
Uninsured foreign cash balance	8,053		8,053
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk percentage	71.00%	76.00%	70.00%	75.00%
Line of Credit [Member]
Significant Accounting Policies [Line Items]
Line of credit, maximum borrowing capacity	1,500,000		1,500,000
Letter of Credit [Member]
Significant Accounting Policies [Line Items]
Line of credit, maximum borrowing capacity	500,000		500,000
Clinical [Member]
Significant Accounting Policies [Line Items]
Payment period from the date of invoice			45 days
Receivable Balance	1,423,646		1,423,646		1,701,837
ResponseDX [Member]
Significant Accounting Policies [Line Items]
Receivable Balance	2,960,312		2,960,312		2,345,222
Bad debt expense	$ 589,917	$ 160,952	$ 897,128	$ 460,883

XML

Stock Option Plans (Schedule of Assumptions Used to Estimate Share-Based Compensation Expense Using Black-Scholes Model) (Details)	9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate
Expected dividend yield
Expected volatility	72.35%
Expected term (in years)	6 years 7 days	[1]
Forfeiture rate	7.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.79%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.80%

[1] Expected term is calculated using SAB 107, Simplified Formula. Management has concluded that the use of the simplified method for calculating the expected term of its common stock option grants is appropriate given the Company's lack of history of option exercises.

XML

Summary of Significant Accounting Policies (Schedule of Estimated Useful Lives) (Details)	9 Months Ended
	Sep. 30, 2012
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Laboratory Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Office Furniture and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Office Furniture and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	Shorter of the useful life (5 to 7 years) or the lease term
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years

XML

Summary of Significant Accounting Policies (Schedule of ResponseDX Revenue) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue, Major Customer [Line Items]
Net revenue	$ 5,403,537	$ 5,100,649	$ 13,220,188	$ 17,730,785
Medicare [Member]
Revenue, Major Customer [Line Items]
Net revenue	1,227,893	1,572,807	3,995,200	4,029,676
ResponseDX [Member]
Revenue, Major Customer [Line Items]
Net revenue	3,023,616	3,340,636	8,809,603	9,425,747
ResponseDX [Member] | Medicare [Member]
Revenue, Major Customer [Line Items]
Net revenue	1,227,893	1,572,807	3,995,200	4,029,675
ResponseDX [Member] | Private Client [Member]
Revenue, Major Customer [Line Items]
Net revenue	1,795,723	1,765,753	4,814,403	5,389,199
ResponseDX [Member] | Other Payor [Member]
Revenue, Major Customer [Line Items]
Net revenue		$ 2,076		$ 6,873

XML

Property and Equipment and Intangible Assets

9 Months Ended

Sep. 30, 2012

Property and Equipment and Intangible Assets [Abstract]

Property and Equipment and Intangible Assets

3. Property and Equipment and Intangible Assets

Property and equipment and intangible assets consist of the following:

	December 31, 2011			September 30, 2012
				(Unaudited)
Laboratory equipment	$	3,036,274		$	3,208,449
Office furniture and equipment		624,859			660,626
Leasehold improvements		194,899			299,434
		3,856,032			4,168,509
Less: Accumulated depreciation		(2,810,745	)		(3,141,947	)
Total property and equipment, net	$	1,045,287		$	1,026,562
Purchased software	$	91,505		$	445,881
Internally developed software		48,461			108,362
		139,966			554,243
Less: Accumulated amortization		(73,151	)		(90,233	)
Total intangible assets, net	$	66,815		$	464,010

Intangible assets are carried at the cost to obtain them. Internally developed intangible assets are amortized using the straight-line method over the estimated useful life of five years. At September 30, 2012, the Company had not yet begun amortizing purchase software costs related to a new laboratory information management system because it had not yet been implemented. The Company expects to deploy the laboratory information management system in early 2013. Depreciation and amortization expense, included in cost of revenue, general and administrative expenses, and research and development expenses, for the three months ended September 30, 2011 and 2012 was $90,606 and $118,153, respectively, and $262,591 and $348,284 for the nine months ended September 30, 2011 and 2012, respectively.

Capital Lease

The Company leases certain equipment that is recorded as capital leases. This equipment is included in property and equipment on the accompanying balance sheet as of September 30, 2012 as follows:

	(Unaudited)
Equipment purchased under capital leases	$	451,234
Less: Accumulated amortization		(170,392	)
Equipment purchased under capital leases, net	$	280,842

Future minimum lease payments under capital leases as of September 30, 2012 are as follows:

Years ending December 31,	(Unaudited)
2012	$	44,907
2013		175,548
2014		87,119
Total minimum lease payments		307,574
Less amount represented by interest		(26,732	)
Less current portion		(158,821	)
Capital lease obligation, net of current portion	$	122,021

XML

Summary of Significant Accounting Policies (Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue, Major Customer [Line Items]
Revenue	$ 5,403,537	$ 5,100,649	$ 13,220,188	$ 17,730,785
Glaxo, Smith, Kline [Member]
Revenue, Major Customer [Line Items]
Revenue	777,571	356,594	1,000,147	2,878,860
Percent of Total Revenue	14.00%	7.00%	8.00%	16.00%
Glaxo Smith Kline Biologicals [Member]
Revenue, Major Customer [Line Items]
Revenue	886,945	1,109,112	1,619,372	4,186,385
Percent of Total Revenue	16.00%	22.00%	12.00%	24.00%
Medicare [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 1,227,893	$ 1,572,807	$ 3,995,200	$ 4,029,676
Percent of Total Revenue	23.00%	31.00%	30.00%	23.00%

XML

Commitments and Contingencies (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Commitments and Contingencies Disclosure [Line Items]
Rent expense	$ 156,088	$ 112,548	$ 508,456	$ 371,553
California State [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating leases, space	20,753		20,753
Operating lease expiration date			Jun. 30, 2013
Maryland [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating leases, space	1,460		1,460
Operating lease expiration date			Jan. 31, 2013

XML

Fair Value Measurements (Details) (Money Market Funds [Member], USD $)	Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market accounts	$ 10,000	[1]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market accounts	10,000	[1]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market accounts		[1]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market accounts		[1]

[1] Included in cash and cash equivalents on the accompanying consolidated balance sheet.

XML

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2012	Dec. 31, 2011
Current assets
Cash and cash equivalents	$ 10,839,201	$ 1,700,295
Accounts receivable, net of allowance for doubtful accounts of $838,750 and $864,419 at December 31, 2011 and September 30, 2012, respectively.	4,383,958	4,047,059
Prepaid expenses and other current assets	447,494	991,351
Total current assets	15,670,653	6,738,705
Property and equipment, net	1,026,562	1,045,287
Intangible assets	464,010	66,815
Total assets	17,161,225	7,850,807
Current liabilities
Accounts payable	1,348,241	1,492,526
Accrued expenses	412,390	1,149,741
Accrued royalties	692,631	738,832
Accrued payroll and related liabilities	1,029,017	1,362,689
Capital lease obligation current portion	158,821	149,253
Line of credit	1,000,000	1,000,000
Deferred revenue	803,481
Total current liabilities	5,444,581	5,893,041
Capital lease obligation, net of current portion	122,021	240,928
Total liabilities	5,566,602	6,133,969
Commitments and contingencies (Note 5)
Common stock classified outside of stockholders' equity (deficit)	19,575,724	7,854,682
Stockholders' equity (deficit)
Common stock, $0.01 par value; 50,000,000 shares authorized; 19,540,358 and 32,797,625 shares issued and outstanding at December 31, 2011 and September 30, 2012, respectively	172,414	134,327
Additional paid-in capital	48,904,324	43,514,591
Accumulated deficit	(56,789,324)	(49,519,585)
Accumulated other comprehensive loss	(268,515)	(267,177)
Total stockholders' equity (deficit)	(7,981,101)	(6,137,844)
Total liabilities, common stock classified outside of stockholders' equity (deficit) and stockholders' equity (deficit)	$ 17,161,225	$ 7,850,807

XML

Stock Option Plans (Summary of Stock Option Activity) (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Number of Shares
Outstanding, December 31, 2011	1,870,846
Granted (Unaudited)	914,200
Exercised (Unaudited)
Expired (Unaudited)	(701,840)
Forfeited (Unaudited)	(182,531)
Outstanding, September 30, 2012 (Unaudited)	1,900,675	1,870,846
Exercisable, September 30, 2012 (Unaudited)	765,672
Weighted Average Exercise Price
Outstanding, December 31, 2011	$ 3.67
Granted (Unaudited)	$ 1.47
Exercised (Unaudited)
Expired (Unaudited)	$ 5.02
Forfeited (Unaudited)	$ 5.83
Outstanding, September 30, 2012 (Unaudited)	$ 2.29	$ 3.67
Exercisable, September 30, 2012 (Unaudited)	$ 3.38
Remaining Contractual Life (Years)
Outstanding, December 31, 2011	9 years 3 months 15 days	7 years 4 months 24 days
Granted (Unaudited)	9 years 7 months 21 days
Expired (Unaudited)	5 years 6 months 22 days
Outstanding, September 30, 2012 (Unaudited)	9 years 3 months 15 days	7 years 4 months 24 days
Exercisable, September 30, 2012 (Unaudited)	6 years 9 months 11 days
Aggregate Intrinsic Value
Outstanding, December 31, 2011	$ 66,976
Granted (Unaudited)	63,541
Outstanding, September 30, 2012 (Unaudited)	63,541	66,976
Exercisable, September 30, 2012 (Unaudited)	$ 2,649

XML

Organization, Operations and Basis of Accounting

9 Months Ended

Sep. 30, 2012

Organization, Operations and Basis of Accounting [Abstract]

Organization, Operations and Basis of Accounting

1. Organization, Operations and Basis of Accounting

Response Genetics, Inc. (the "Company") is a life sciences company engaged in the pharmacogenomic research, development, marketing and sale of tests for use in the diagnosis and treatment of cancer. The Company was incorporated in the state of Delaware on September 23, 1999 as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Pharmacogenomics is the science of how an individual's genetic makeup relates to drug response. Tests based on pharmacogenomics facilitate the prediction of a response to drug therapy or survival following surgery based on an individual's genetic makeup. In order to generate information from patient specimens for these tests, the Company developed and patented methods for maximizing the extraction and analysis of nucleic acids and, therefore, accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as global gene interrogation using microarray methods from paraffin or frozen tissue specimens. The Company continues to also expand its platforms utilizing multiple approaches thereby providing what the Company believes is better patient care. The Company primarily derives its revenue from the sale of its ResponseDX^® diagnostic testing products and by providing testing services to pharmaceutical companies in the United States, Asia and Europe.

The Company's goal is to provide cancer patients and their physicians with a means to make informed, individualized treatment decisions based on genetic analysis of tumor tissues. The Company's analysis of clinical trial specimens for the pharmaceutical industry may provide data that will lead to a better understanding of the molecular basis for response to specific drugs and, therefore lead to individualized treatment.

Since its inception, the Company has devoted substantial effort in developing its products and has incurred losses and negative cash flows from operations. At September 30, 2012, the Company had an accumulated deficit of $56,789,324. The Company anticipates continued losses and negative cash flows as it funds its selling and marketing activities and research and development programs.

The Company's current operating plan includes various assumptions concerning the level and timing of cash receipts from product sales and cash outlays for operating expenses and capital expenditures. The Company's ability to successfully carry out its business plan is primarily dependent upon its ability to (1) obtain sufficient capital at acceptable costs, (2) attract and retain knowledgeable workers, and (3) generate significant revenues.

However, if events or circumstances occur such that the Company does not meet its operating plan as expected, in addition to seeking additional capital, the Company will most likely be required to reduce certain spending, which could have a material adverse effect on the Company's ability to achieve its intended business objectives. No adjustments have been made to the accompanying financial statements to reflect any of the matters discussed above.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions for Form 10-Q promulgated by the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for interim periods are not necessarily indicative of the results that may be expected for the fiscal year. The financial statements should be read in conjunction with the Company's audited December 31, 2010 and 2011 consolidated financial statements and accompanying notes included in the Company's Form 10-K and 10-K/A previously filed with the SEC.

XML

Property and Equipment and Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Property and Equipment and Intangible Assets [Abstract]
Depreciation expense	$ 118,153	$ 90,606	$ 348,284	$ 262,591

XML

Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Loss Per Share [Abstract]

Computation for Basic and Diluted Loss Per Share

	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2012			2011			2012
	( Unaudited )						( Unaudited )
Numerator:
Net loss	$	(1,415,540	)	$	(1,415,488	)	$	(1,759,775	)	$	(7,269,739	)
Numerator for basic and diluted earnings per share	$	(1,415,540	)	$	(1,415,488	)	$	(1,759,775	)	$	(7,269,739	)
Denominator:
Denominator for basic and diluted earnings per share - weighted-average shares		19,537,232			26,362,842			18,979,010			24,709,185
Basic and diluted loss per share	$	(0.07	)	$	(0.05	)	$	(0.09	)	$	(0.29	)

XML

Property and Equipment and Intangible Assets (Schedule of Capital Leased Assets) (Details) (USD $)	Sep. 30, 2012
Property and Equipment and Intangible Assets [Abstract]
Equipment purchased under capital leases	$ 451,234
Less: Accumulated amortization	(170,392)
Equipment purchased under capital leases, net	$ 280,842

XML

Stock Option Plans (Tables)

9 Months Ended

Sep. 30, 2012

Stock Option Plans [Abstract]

Schedule of Assumptions Used to Estimate Share-Based Compensation Expense Using Black-Scholes Model

	Three Months Ended September 30,
	2011		2012
Risk free interest rate		-		0.79 - 0.80	%
Expected dividend yield		-		-
Expected volatility		-		72.35	%
Expected term **(in years)		-		6.02
Forfeiture rate		-		7.00	%

** Expected term is calculated using SAB 107, Simplified Formula. Management has concluded that the use of the simplified method for calculating the expected term of its common stock option grants is appropriate given the Company's lack of history of option exercises.

Summary of Stock Option Activity

	Number of Shares			Weighted Average Exercise Price		Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2011		1,870,846		$	3.67		7.40	$	66,976
Granted (Unaudited)		914,200		$	1.47		9.64		63,541
Exercised (Unaudited)		-		$	-		-		-
Expired (Unaudited)		(701,840	)		5.02		5.56		-
Forfeited (Unaudited)		(182,531	)	$	1.83		-		-
Outstanding, September 30, 2012 (Unaudited)		1,900,675		$	2.29		9.29	$	63,541
Exercisable, September 30, 2012 (Unaudited)		765,672		$	3.38		6.78	$	2,649

Schedule of Options Outstanding

		Options Outstanding				Options Exercisable
Exercise Price		Number of Options		WA Remaining Contractual Term		Number of Options		WA Remaining Contractual Term
$	1.16 to 1.17		490,700		9.83		20,459		9.83
	1.32 to 1.35		196,316		7.09		141,233		6.71
	1.65 to 1.67		327,750		9.22		5,210		9.66
	1.86 to 2.06		220,000		9.49		16,044		9.48
	2.21 to 2.35		285,500		8.10		235,500		8.21
	2.71 to 3.24		172,409		6.83		139,226		6.60
	3.80 to 4.29		23,000		5.20		23,000		5.20
	7.00		185,000		4.69		185,000		4.69
			1,900,675		8.31		765,672		6.78

Schedule of Stock Based Compensation Included in Results of Operations

	Three Months Ended September 30,				Nine Months Ended September 30,
	( Unaudited )				( Unaudited )
	2011		2012		2011		2012
Cost of revenue	$	61,395	$	12,603	$	208,672	$	46,839
Research and development		10,951		17,167		37,221		29,591
Sales and marketing		5,521		11,277		18,765		39,337
General and administrative		128,852		121,466		439,113		568,130
Totals	$	206,719	$	162,513	$	703,771	$	683,897

Schedule of Awards to Mr. Bologna

Type	Grant Date		Number of Awards		Intrinsic Value as of September 30, 2012		Exercise Price		Options Exercisable		Remaining Contractual Term
Restricted Shares of Common Stock		12/21/2011		270,000	$	13,500	$	-		-		9.2
Options		12/21/2011		600,000	$	30,000	$	1.20		150,000		9.2
Options		12/21/2011		300,000	$	15,000	$	1.20		300,000		9.2

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Response Genetics, Ltd., a Scottish corporation, which was incorporated in November 2006. All significant intercompany transactions and balances have been eliminated in consolidation.

Reclassification

Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company's financial condition as of December 31, 2011 nor statement of operations for the period ended September 30, 2011.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity date of three months or less from the date of purchase to be cash equivalents. The carrying value of cash equivalents approximates fair value due to the short-term nature and liquidity of these instruments. The Company's cash equivalents are comprised of cash on hand, deposits in banks and money market investments.

Accounts Receivable

Pharmaceutical Accounts Receivable

The Company invoices its clients as specimens are processed and any other contractual obligations are met. The Company's contracts with clients typically require payment within 45 days of the date of invoice. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its clients to make required payments. The Company specifically analyzes accounts receivable and historical bad debts, client credit, current economic trends and changes in client payment trends when evaluating the adequacy of the allowance for doubtful accounts. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered. To date, the Company's pharmaceutical customers have primarily been large pharmaceutical companies. As a result, bad debts from pharmaceutical accounts receivable to date have been minimal. Pharmaceutical company accounts receivable as of December 31, 2011 and September 30, 2012 were $1,701,837 and $1,423,646, respectively. There were no allowances for doubtful accounts recorded against these pharmaceutical accounts receivable at December 31, 2011 and September 30, 2012.

ResponseDX^® Accounts Receivable

ResponseDX^® accounts receivable are recorded from two primary payors: Medicare and third party and private payors ("Private Payors"). ResponseDX^® accounts receivable are recorded at established billing rates less an estimated billing adjustment, based on reporting models utilizing historical cash collection percentages and updated for current effective reimbursement factors. Management performs ongoing valuations of accounts receivable balances based on management's evaluation of historical collection experience and industry trends in order to record an allowance for doubtful accounts. Based on the historical experience for the Company's Medicare and Private Payor accounts, management has determined that related accounts receivable associated with billings over one year are unlikely to be collected. Any outstanding receivable balance that is over one year old is written off. The Company's bad debt expense for the three months ended September 30, 2011 and 2012, was $160,952 and $589,917, respectively, and $460,883 and $897,128 for the nine months ended September 30, 2011 and 2012.

ResponseDX^® accounts receivable as of December 31, 2011 and September 30, 2012, consisted of the following:

	December 31, 2011			September 30, 2012
				(Unaudited)
Net Medicare receivable	$	506,308		$	774,237
Net Private Payor receivable		2,634,838			3,050,494
Other		42,826			-
		3,183,972			3,824,731
Allowance for doubtful accounts		(838,750	)		(864,419	)
Total	$	2,345,222		$	2,960,312

Property and Equipment

Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the double declining balance and straight-line methods over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows:

Laboratory equipment	5 to 7 years
Furniture and Equipment	5 to 7 years
Leasehold Improvements	Shorter of the useful life (5 to 7 years) or the lease term

Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. The Company has capitalized costs related to the development of database software (see Note 3). The portion of this database placed into service is amortized in accordance with ASC 350-40, Internal-Use Software. The amortization period is three years using the straight-line method.

Revenue Recognition

Pharmaceutical Revenue

Revenues that are derived from testing services provided to pharmaceutical companies are recognized on a contract specific basis pursuant to the terms of the related agreements. Revenue is recognized in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.

Revenues are recorded on an accrual basis as the contractual obligations are completed and as a set of assays is processed through the Company's laboratory under a specified contractual protocol and are recorded on the date the tests are resulted. Certain contracts have minimum assay requirements that, if not met, result in payments that are due upon the completion of the designated period. In these cases, revenues are recognized when the end of the specified contract period is reached.

On occasion, the Company may enter into a contract that requires the client to provide an advance payment for specimens that will be processed at a later date. In these cases, the Company records this advance as deferred revenue and recognizes the revenue as the specimens are processed or at the end of the contract period, as appropriate.

ResponseDX^® Revenue

Revenues that are derived from ResponseDX^® testing services are recognized in accordance with ASC 605, Revenue Recognition , which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered. (3) the price is fixed or determinable; and (4) collectability is reasonably assured. We record revenues when our tests have confirmed results which is evidence that the services have been performed.

Revenues are recorded on an accrual basis as the contractual obligations are completed and as a set of assays is processed through our laboratory under a specified contractual protocol.

ResponseDX^® Private Payor and Medicare revenues are recorded on an accrual basis at established billing rates less an estimated billing adjustment, based on reporting models utilizing historical cash collection percentages and updated for current effective reimbursement factors. The Company's Medicare provider number allows it to invoice and collect from Medicare. The Company's invoicing to Medicare is primarily based on amounts allowed by Medicare for the service provided as defined by Common Procedural Terminology ("CPT").

The following details ResponseDX^® revenue for the three and nine months ended September 30, 2011 and 2012:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	(Unaudited)				(Unaudited)
	2011		2012		2011		2012
Net Medicare revenue	$	1,572,807	$	1,227,893	$	4,029,675	$	3,995,200
Private Payor revenue		1,765,753		1,795,723		5,389,199		4,814,403
Other		2,076		-		6,873		-
Net ResponseDX® revenue	$	3,340,636	$	3,023,616	$	9,425,747	$	8,809,603

Cost-Containment Measures

Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of health care services, which include diagnostic test providers such as the Company, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.

Regulatory Matters

A portion of the Company's revenues are derived from Medicare reimbursement. Laws and regulations governing Medicare programs are complex and subject to interpretation, and the Company may be adversely affected by future governmental investigations, lawsuits or private actions which include mandatory damages, fines, penalties, criminal charges, loss of suspension of licenses and/or suspension or exclusion from Medicare and certain other governmental programs. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing.

Medicare reimbursement rates are subject to regulatory changes and government funding restrictions. The Company is aware of public comments and associated commentary related to future rate changes that may occur in early 2013. Significant changes to the reimbursement rates could have a material adverse effect on the Company's operations.

Cost of Revenue

Cost of revenue represents the cost of materials, direct labor, royalties, costs associated with processing tissue specimens including pathological review, staining, microdissection, paraffin extraction, reverse transcription polymerase chain reaction, ALK Break Apart fluorescence in situ hybridization (FISH), quality control analyses, license fees and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.

License Fees

The Company has licensed technology for the extraction of mRNA from formalin-fixed, paraffin-embedded tumor specimens from the University of Southern California ("USC"). Under the terms of the license agreement, the Company is required to pay royalties to USC based on the revenue generated by use of this technology. The Company maintains a non-exclusive license to use certain patents related to the polymerase chain reaction ("PCR") of Roche Molecular Systems, Inc. ("Roche"). The Company pays Roche a royalty fee based on revenue that the Company generates through use of this technology. The Company accrues for such royalties at the time revenue is recognized. Such royalties are included in cost of revenues in the accompanying statements of operations.

Research and Development

The Company expenses costs associated with research and development activities as incurred. Research and development costs are expensed as incurred in relation to direct costs that can be identified and classified as research and development costs. Certain costs such as lab supplies and reagents that cannot be specifically identified are allocated based on the number of samples processed in total by the lab and R&D departments in total. Research and development costs include employee costs (salaries, payroll taxes, benefits, and travel), equipment depreciation and warranties and maintenance, laboratory supplies, primers and probes, reagents, patent costs and occupancy costs.

Line of Credit

On July 14, 2011, the Company entered into a line of credit agreement with Silicon Valley Bank (the "Bank"). The agreement has been amended most recently on September 28, 2012. The line of credit is collateralized by the Company's pharmaceutical and Medicare receivables. The amended maximum amount that can be borrowed from the credit line is $2,000,000. The amount the Company can draw from the loan is equal to the calculated borrowing base, which is 80% of the Company's pharmaceutical accounts receivable that have not aged greater than 90 days. As of September 30, 2012, the amount available for the borrowing base is fixed at $1,500,000 until November 30, 2012. As part of the line of credit the Bank will issue letters of credit up to a maximum amount of $500,000. Any issued letters of credit reduce the amount available to borrow under the line of credit on a dollar for dollar basis. The interest fees associated with this line of credit are set at the prime rate plus 1%. For the period ended September 30, 2012, the rate being charged to the Company was 5%. As needed from time to time, the Company may draw on this line for use for general corporate purposes. As of December 31, 2011 and September 30, 2012, the Company has drawn $1,000,000 against the line of credit and no letters of credit were outstanding. The line of credit is subject to various financial covenants and, as of September 30, 2012, the Company was not in compliance with certain covenants. The September 28, 2012 amendment provided forbearance for the failure to comply with these certain covenants through November 30, 2012, and the amendment modified the covenants to include a requirement that the Company maintain account balances at the Bank totaling a minimum of $4,000,000 during the forbearance period. Management intends to utilize the forbearance period to restructure the line of credit agreement and any related covenant compliance issues. As of December 31, 2011, and September 30, 2012, the line of credit was classified as a current liability of the Company on the accompanying balance sheet. However, there can be no assurance that the Company will be able to restructure the line of credit agreement during the forbearance period on terms acceptable to the Company, or at all, nor can there be any assurance that the Company will be able to resolve all such covenant compliance issues during the forbearance period.

From time to time the Company's borrowing base under its Bank line of credit may decrease to a level where the Company is in an over-advance position. This occurred on one occasion during the second quarter of 2012 based on the May 2012 borrowing base, as a result of which the Company was required to repay $298,000 to the Bank. The Company drew down the same amount one week later once the June 2012 borrowing base was determined to be sufficiently higher than the May 2012 borrowing base, thereby giving the Company the capacity to borrow such additional amount.

Income Taxes

Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

ASC 740, Income Taxes , clarifies the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of December 31, 2011 and September 30, 2012, the Company does not have a liability for unrecognized tax benefits. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related tax liability in the balance sheet. For the period ended September 30, 2012 there were no interest or penalties recorded on the Consolidated Statement of Operations.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Stock Compensation, Share-Based Payment. Stock-based compensation expense for all stock-based compensation awards granted is based on the grant-date fair value estimated in accordance with the provisions of ASC 718. The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting period. As further described in Note 7, certain awards granted to Thomas Bologna, the Company's Chairman and Chief Executive Officer, were recognized based on an accelerated vesting basis triggered by market conditions rather than a straight-line basis.

The Company accounts for equity instruments issued to non-employees in accordance with ASC 505, Equity . Under ASC 505, stock option awards issued to non-employees are measured at fair value using the Black-Scholes option-pricing model and recognized pursuant to a performance model.

Management Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates in these consolidated financial statements have been made for revenue, allowances for contractual and doubtful accounts, impairment of long-lived assets, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.

Long-lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates potential impairment by comparing the carrying amount of the asset with the estimated undiscounted future cash flows associated with the use of the asset and its eventual disposition. Should the review indicate that the assets cost is not recoverable, the carrying value of the asset would be reduced to its estimated fair value, which is measured by future discounted cash flows.

Foreign Currency Translation

The financial position and results of operations of the Company's foreign subsidiary are determined using local currency as the functional currency. Assets and liabilities of these operations are translated at the exchange rate in effect at each period-end. Statement of Operations amounts are translated at the average rate of exchange prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss in stockholders' equity (deficit).

Comprehensive Loss

The components of comprehensive loss are accumulated net loss and unrealized foreign currency translation adjustments for the three and nine months ended September 30, 2011 and 2012.

Fair Value of Financial Instruments

For cash and cash equivalents, accounts receivable, accounts payable, capital lease obligations and the line of credit the carrying amount approximates fair market value. Cash equivalents consist of money market accounts, with fair values estimated based on quoted market prices. For additional information see Note 12.

Advertising Costs

The Company markets its services through its advertising activities in trade publications and on-line. Advertising costs are included in selling and marketing expenses on the statements of operations and are expensed as incurred. Advertising costs for the three months ended September 30, 2011 and 2012 were $16,985 and $655, respectively and $83,462 and $13,626 for the nine months ended September 30, 2011 and 2012, respectively.

Concentration of Credit Risk and Clients and Limited Suppliers

Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All of the Company's non-interest bearing cash balances were fully insured at September 30, 2012 due to a temporary federal program in effect from December 31, 2011 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning on January 1, 2013, federal insurance coverage is scheduled to revert to $250,000 per depositor at each financial institution, and the Company's non-interest bearing cash balances may again exceed federally insured limits. There were no funds in interest-bearing accounts that exceeded the federally insured limits as of September 30, 2012. At September 30, 2012, $8,053 of cash was held outside of the United States and is uninsured.

Revenue sources that account for greater than 10 percent of total revenue are provided below.

	Three Months Ended September 30,										Nine Months Ended September 30,
	2011					2012					2011					2012
	(Unaudited)										(Unaudited)
	Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue
GlaxoSmithKline	$	356,594		7	%	$	777,571		14	%	$	2,878,860		16	%	$	1,000,147		8	%
GlaxoSmithKline Biologicals	$	1,109,112		22	%	$	886,945		16	%	$	4,186,385		24	%	$	1,619,372		12	%
Medicare, net of contractual allowances	$	1,572,807		31	%	$	1,227,893		23	%	$	4,029,676		23	%	$	3,995,200		30	%

Customers that account for greater than 10 percent of gross accounts receivable are provided below.

	As of December 31, 2011					As of September 30, 2012
	( Unaudited )					( Unaudited )
	Receivable Balance		Percent of Total Receivables			Receivable Balance		Percent of Total Receivables
GlaxoSmithKline	$	476,526		10	%	$	275,553		5	%
GlaxoSmithKline Biologicals	$	1,079,570		22	%	$	276,206		5	%
Medicare, net of contractual allowances	$	506,308		10	%	$	774,237		15	%

Many of the supplies and reagents used in the Company's testing process are procured from a limited number of suppliers. Any supply interruption or an increase in demand beyond the suppliers' capabilities could have an adverse impact on the Company's business. Management believes it could identify alternative sources, if necessary, but it is possible such sources may not be identified in sufficient time to avoid an adverse impact on the Company's business. Refer also to Note 6 for further discussion regarding these supply agreements. The Company purchases certain laboratory supplies and reagents primarily from two suppliers and purchases from these two companies accounted for approximately 76% and 71% of the Company's reagent purchases for the three months ended September 30, 2011 and 2012, respectively and approximately 75% and 70% for the nine months ended September 30, 2011 and 2012, respectively.

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
CONSOLIDATED BALANCE SHEETS [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 864,419	$ 838,750
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	32,797,625	19,540,358
Common stock, shares outstanding	32,797,625	19,540,358

XML

Fair Value Measurements

9 Months Ended

Sep. 30, 2012

Fair Value Measurements [Abstract]

Fair Value Measurements

12. Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. ASC 820 establishes a three-level valuation hierarchy of valuation techniques that is based on observable and unobservable inputs. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The first two inputs are considered observable and the last unobservable, that may be used to measure fair value and include the following:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of September 30, 2012, the Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis, including its cash and cash equivalents. The fair value of these assets and liabilities was determined using the following inputs in accordance with ASC 820 at September 30, 2012:

	Fair Value Measurement as of September 30, 2012 (Unaudited)
	Total		Level 1		Level 2		Level 3
Description	$		$		$		$
Money market accounts (1)		10,000		10,000		-		-

(1) Included in cash and cash equivalents on the accompanying consolidated balance sheet.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2012	Nov. 09, 2012
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Entity Registrant Name	RESPONSE GENETICS INC
Entity Central Index Key	0001124608
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		32,797,625

XML

Subsequent Events

9 Months Ended

Sep. 30, 2012

Subsequent Events [Abstract]

Subsequent Events

13. Subsequent Events

As described above, pursuant to the registration rights agreement, dated September 13, 2012, the Company filed a registration statement with the SEC on October 26, 2012, to register for resale 8,000,000 shares of common stock of the Company issued to certain investors on September 13, 2012. This registration statement became effective on November 13, 2012.

XML

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS [Abstract]
Net revenue	$ 5,403,537	$ 5,100,649	$ 13,220,188	$ 17,730,785
Operating expenses:
Cost of revenue	2,768,894	2,538,176	7,895,870	8,040,003
Selling and marketing	1,195,988	1,251,054	4,145,115	4,107,639
General and administrative	2,407,544	2,268,517	6,686,559	6,493,079
Research and development	426,105	452,734	1,695,851	838,622
Total operating expenses	6,798,531	6,510,481	20,423,395	19,479,343
Operating loss	(1,394,994)	(1,409,832)	(7,203,207)	(1,748,558)
Other income (expense):
Interest expense	(20,497)	(5,804)	(66,556)	(11,379)
Interest income	3	96	24	162
Net loss	(1,415,488)	(1,415,540)	(7,269,739)	(1,759,775)
Unrealized gain (loss) on foreign currency translation	968	(25,593)	(1,338)	(25,593)
Total comprehensive loss	$ (1,414,520)	$ (1,441,133)	$ (7,271,077)	$ (1,785,368)
Net loss per share - basic and diluted	$ (0.05)	$ (0.07)	$ (0.29)	$ (0.09)
Weighted-average shares - basic and diluted	26,362,842	19,537,232	24,709,185	18,979,010

XML

Stock Option Plans

9 Months Ended

Sep. 30, 2012

Stock Option Plans [Abstract]

Stock Option Plans

7. Stock Option Plans

In March 2000, the Company adopted a Stock Option Plan (the "2000 Stock Plan") as approved by its Board of Directors. Under the 2000 Stock Plan, the Company granted options to acquire up to 1,600,000 shares of common stock. In connection with the adoption of the 2006 Employee, Director and Consultant Stock Plan, as further discussed below, the Company is to grant no additional options under the 2000 Stock Plan. Under the 2000 Stock Plan, there were no options to purchase shares that remained outstanding as of September 30, 2012. No more options may be granted under the 2000 Stock Plan. The Company also granted options to purchase 16,000 shares of common stock to two consultants which were granted under separate agreements outside of the 2000 Stock Plan.

On October 26, 2006, the Board of Directors of the Company approved, and on May 1, 2007, reapproved the adoption of the 2006 Employee, Director and Consultant Stock Plan (the "2006 Stock Plan"). The stockholders approved the 2006 Stock Plan on June 1, 2007. The initial number of shares which may be issued from time to time pursuant to the 2006 Stock Plan was 2,160,000 shares of common stock. In addition, on the first day of each fiscal year of the Company during the period beginning in fiscal year 2008, and ending on the second day of fiscal year 2017, the number of shares that may be issued from time to time pursuant to the 2006 Stock Plan is increased by the lesser of (i) 200,000 shares or equivalent, after determination of the effect of any stock split, stock dividend, combination or similar transactions as set forth in the 2006 Stock Plan, (ii) 5% of the number of outstanding shares of common stock of the Company on such date or (iii) an amount determined by the board of directors of the Company. The initial number of shares available for issuance of 2,160,000 increased by 200,000 in 2008, 2009, 2010, 2011 and 2012, resulting in the total number of shares that may be issued as of January 1, 2012 to be 3,160,000. As of September 30, 2012, there were 1,059,325 options available for grant under the 2006 Stock Plan.

Employee options vest according to the terms of the specific grant and expire 10 years from the date of grant. Non-employee option grants to date typically vest over a 2 to 3 year period. The Company had 1,900,675 options outstanding at a weighted average exercise price of $2.29 at September 30, 2012. There were 1,135,003 non-vested stock options outstanding with a weighted average grant date fair value of $1.05 at September 30, 2012. As of September 30, 2012, there was $886,077 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 Stock Plan. That cost is expected to be recognized over a weighted-average period of 2.47 years.

Except for the certain grants of restricted common stock and common stock options containing market conditions as described below, the Company estimated share-based compensation expense for the three months ended September 30, 2011 and 2012 using the Black-Scholes model with the following weighted average assumptions:

	Three Months Ended September 30,
	2011		2012
Risk free interest rate		-		0.79 - 0.80	%
Expected dividend yield		-		-
Expected volatility		-		72.35	%
Expected term **(in years)		-		6.02
Forfeiture rate		-		7.00	%

** Expected term is calculated using SAB 107, Simplified Formula. Management has concluded that the use of the simplified method for calculating the expected term of its common stock option grants is appropriate given the Company's lack of history of option exercises.

The following table summarizes the stock option activity for the 2006 Plan for the nine months ended September 30, 2012:

	Number of Shares			Weighted Average Exercise Price		Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2011		1,870,846		$	3.67		7.40	$	66,976
Granted (Unaudited)		914,200		$	1.47		9.64		63,541
Exercised (Unaudited)		-		$	-		-		-
Expired (Unaudited)		(701,840	)		5.02		5.56		-
Forfeited (Unaudited)		(182,531	)	$	1.83		-		-
Outstanding, September 30, 2012 (Unaudited)		1,900,675		$	2.29		9.29	$	63,541
Exercisable, September 30, 2012 (Unaudited)		765,672		$	3.38		6.78	$	2,649

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2011 and 2012 was $2.27 and $1.47, respectively.

The following table provides additional information regarding options outstanding under the 2006 Plan as of September 30, 2012 (Unaudited):

		Options Outstanding				Options Exercisable
Exercise Price		Number of Options		WA Remaining Contractual Term		Number of Options		WA Remaining Contractual Term
$	1.16 to 1.17		490,700		9.83		20,459		9.83
	1.32 to 1.35		196,316		7.09		141,233		6.71
	1.65 to 1.67		327,750		9.22		5,210		9.66
	1.86 to 2.06		220,000		9.49		16,044		9.48
	2.21 to 2.35		285,500		8.10		235,500		8.21
	2.71 to 3.24		172,409		6.83		139,226		6.60
	3.80 to 4.29		23,000		5.20		23,000		5.20
	7.00		185,000		4.69		185,000		4.69
			1,900,675		8.31		765,672		6.78

Stock-based compensation expense was classified as follows in the results of operation:

	Three Months Ended September 30,				Nine Months Ended September 30,
	( Unaudited )				( Unaudited )
	2011		2012		2011		2012
Cost of revenue	$	61,395	$	12,603	$	208,672	$	46,839
Research and development		10,951		17,167		37,221		29,591
Sales and marketing		5,521		11,277		18,765		39,337
General and administrative		128,852		121,466		439,113		568,130
Totals	$	206,719	$	162,513	$	703,771	$	683,897

Thomas Bologna was appointed Chief Executive Officer of the Company on December 21, 2011, and in connection with his appointment, Mr. Bologna was awarded stock options outside of the 2006 Stock Plan. Pursuant to the employment agreement between the Company and Mr. Bologna, dated December 21, 2011, and in reliance on NASDAQ Listing Rule 5636(c), the Company granted Mr. Bologna (i) a stock option to purchase 600,000 shares of the Company's common stock, which vests monthly over 36 months from the date of grant, subject to his continued employment with the Company, (ii) a stock option to purchase 300,000 shares of the Company's common stock, which vests in two equal installments on the first day of the 18th and 36th calendar months from the date of grant, subject to his continued employment with the Company, or if earlier, the date on which the 30-day trailing average closing price of the Company's common stock equals or exceeds $1.80, and (iii) 270,000 shares of restricted shares of common stock of the Company, which vest on the date on which the 30-day trailing average closing price of the Company's common stock equals or exceeds $2.40. The exercise price of the stock options is $1.20 per share, the closing price of the Company's common stock on the day prior to the date of grant. The expense recognized in connection with these grants was $104,468 and $440,133 for the three and nine months ended September 30, 2012, respectively, and is included in the above table.

Since the restricted shares of common stock grant vests upon attainment of a target price for the Company's common stock and each tranche of the 300,000 share common stock option grant can vest sooner than the stated vesting dates based upon attainment of a target price for the Company's common stock, these awards are deemed to include market conditions for purposes of determining the valuation and accounting for the awards. Accordingly, the fair value of the restricted shares of common stock grant and each tranche of the 300,000 share common stock option grant that Mr. Bologna received was determined using a Monte-Carlo simulation model to simulate the Company's stock prices in the future that would trigger or not trigger the market conditions. For these awards containing market conditions, the compensation amount will be attributed over the service date unless vesting occurs sooner due to achieving the market condition.

The following table summarizes the awards to Mr. Bologna:

Type	Grant Date		Number of Awards		Intrinsic Value as of September 30, 2012		Exercise Price		Options Exercisable		Remaining Contractual Term
Restricted Shares of Common Stock		12/21/2011		270,000	$	13,500	$	-		-		9.2
Options		12/21/2011		600,000	$	30,000	$	1.20		150,000		9.2
Options		12/21/2011		300,000	$	15,000	$	1.20		300,000		9.2

During the first quarter of 2012, Mr. Bologna's stock award of 300,000 shares met the conditions for vesting in that the 30-day trailing average closing price of the Company's common stock exceeded $1.80. The Company recognized expense of $129,000 for the vesting of this tranche of options for Mr. Bologna's stock awards during the quarter ended March 31, 2012.

XML

License and Collaborative Agreements

9 Months Ended

Sep. 30, 2012

License and Collaborative Agreements [Abstract]

License and Collaborative Agreements

6. License and Collaborative Agreements

License Agreement with the University of Southern California ("USC")

In April 2000, as amended in June 2002 and April 2005, the Company entered into a license agreement with USC. Under this agreement, USC granted the Company a worldwide, exclusive license with the right to sublicense, the patents for RGI-1 and related technology, for use in human and veterinary diagnostic laboratory services, the sale of clinical diagnostic products, and the sale of research products to the research community. USC retains the right under the agreement to use the technology for research and educational purposes.

In consideration for this license, the Company agreed to pay USC royalties based on a percentage of the revenues generated by the use of RGI-1 and related technology. Royalty expense relating to this agreement amounted to $123,873 and $98,740 for the three months ended September 30, 2011 and 2012, respectively and $382,685 and $231,180 for the nine months ended September 30, 2011 and 2012, respectively. Such expense is included in cost of revenue in the accompanying statements of operations.

License Agreement with Roche Molecular Systems ("Roche")

In November 2004, the Company entered into a non-exclusive license to use Roche's PCR processes. In consideration for these rights, the Company is obligated to pay royalties to Roche, based on a percentage of net sales of products or services that make use of the PCR technology. Royalty expense included in cost of revenue relating to this agreement amounted to $116,867 and $105,170 for the three months ended September 30, 2011 and 2012, respectively and $425,232 and $249,057 for the nine months ended September 30, 2011 and 2012, respectively.

Services Agreement with Taiho Pharmaceutical Co., Ltd. ("Taiho")

In July 2001, the Company entered into an agreement with Taiho pursuant to which it will provide Taiho with RGI-1 generated molecular-based tumor analyses for use in guiding chemotherapy treatment for cancer patients and for use in its business developing and marketing pharmaceutical and diagnostic products for use against cancer. Pursuant to the agreement, the Company appointed Taiho as the exclusive purchaser in Japan of tests and testing services based upon the RGI-1 using gene expression for (i) any one or the combination of specified molecular markers, (ii) the therapeutic use of specified compounds, or (iii) the diagnosis or therapeutic treatment of specified precancerous and cancerous diseases. The Company also granted Taiho the right to be a non-exclusive purchaser in Japan of tests and testing services based upon the RGI-1 using gene expression, other than those for which Taiho has exclusivity, for, (i) any one or combination of molecular markers, (ii) the therapeutic use of any compound or biological product against cancer, or (iii) the diagnosis or therapeutic treatment of precancerous and cancerous diseases.

In consideration for the testing services provided, Taiho paid an upfront payment at the commencement of the agreement and is obligated to pay regular testing fees, covering the specific services performed on a monthly basis. In January 2011, the Company amended its agreement with Taiho and the agreement was renewed for an additional three years. According to the terms of the renewal, Taiho's appointment as an exclusive purchaser in Japan of certain tests and testing services and its minimum purchasing obligations ended on December 31, 2011.

Until its minimum purchasing obligations ended on December 31, 2011, Taiho was obligated to purchase a minimum amount of testing services from the Company each calendar quarter. Revenue recognized under this agreement was $158,500 and $585,625 for the three months ended September 30, 2011 and 2012, respectively and $803,600 and $1,122,425 for the nine months ended September 30, 2011 and 2012, respectively.

Services Agreement with GlaxoSmithKline, LLC formerly known as SmithKline Beecham Corporation (d.b.a. GlaxoSmithKline or "GSK")

In January 2006, the Company entered into a master services agreement with GSK, a leading pharmaceutical manufacturer, pursuant to which the Company provides services in connection with profiling the expression of various genes from a range of human cancers. Under the agreement, the Company will provide GSK with testing services as described in individual protocols and GSK will pay the Company for such services based on the pricing schedule established for each particular protocol. GSK is obligated to make minimum annual payments to the Company under the agreement and also was obligated to make a non-refundable upfront payment to the Company, to be credited against work undertaken pursuant to the agreement. In January 2006, the Company received an upfront payment of $2,000,000, which was initially recorded as deferred revenue. There was no remaining deferred revenue balance associated with this agreement as of December 31, 2011.

In December 2008, the Company amended and restated its master services agreement with GSK and extended the term of the agreement for a two-year period, with the option for the parties to extend the agreement for additional one-year periods, upon their mutual written agreement. In addition, the Company became a preferred provider to GSK and its affiliates of genetic testing services on a fee-for-service basis and, in anticipation of the services to be provided, GSK agreed to make a non-refundable upfront payment of approximately $1,300,000, which was received in January 2010. There was no amount of deferred revenue balance associated with this agreement as of December 31, 2011.

The Company recognized revenue of $356,594 and $777,571 relating to the GSK agreement for the three months ended September 30, 2011 and 2012, respectively and $2,878,860 and $1,000,147 for the nine months ended September 30, 2011 and 2012, respectively.

Non-Exclusive License Agreement with GSK

In March 2010, the Company entered into a non-exclusive license agreement with GSK. Under the agreement, the Company granted GSK a non-exclusive, sublicenseable license to its proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. As part of the agreement, the Company received a non-refundable technology access fee in consideration for the transfer of the Company's technology to GSK. The agreement also contains milestone provisions which would allow the Company to earn further payments from GSK. As of September 30, 2012, the Company had earned a $500,000 milestone payment from GSK.

Master Services Agreement with GlaxoSmithKline Biologicals S.A. ("GSK Bio")

On July 26, 2012, the Company entered into a second amended and restated master services agreement with GSK Bio, the vaccine division of GSK. Pursuant to this agreement, which has an effective date of May 15, 2012, the Company will provide testing services for clinical trials and epidemiology studies relating to GSK Bio's cancer immunotherapies. The Company will perform these testing services on a fee-for-service basis as embodied in written task orders. The agreement will expire on December 31, 2014, and is terminable by GSK Bio, without cause, upon 90 days' written notice to the Company.

The Company recognized revenue of $1,109,112 and $886,945 relating to the services performed for GSK Bio for the three months ended September 30, 2011 and 2012, respectively, and $4,186,385 and $1,619,372 for the nine months ended September 30, 2011 and 2012.

Collaboration Agreement with Shanghai BioChip Company, Ltd. ("SBC")

On March 5, 2007, the Company entered into a collaboration agreement with SBC pursuant to which SBC provides exclusive testing services to the Company's clients in China.

Pursuant to the agreement, the Company has granted SBC an exclusive license in China to provide services in China using the Company's proprietary RNA extraction technologies. Subject to consent from USC, the Company granted SBC an exclusive sublicense to patents licensed from USC for distribution of testing services in China. In turn, SBC performs RNA extraction from formalin-fixed paraffin-embedded ("FFPE") tissue specimens exclusively for the Company during the term of the agreement.

This agreement had an initial term of five years, with an automatic renewal for an additional three-year term unless either party gives 90 days' notice in advance of the renewal date of its intent not to renew. As neither party gave notice of intent not to renew, the agreement has automatically renewed for a successive three year period. Pursuant to the agreement, SBC receives a percentage of the gross margin, as defined in the agreement, collected from the Company's clients in China as compensation for its testing services performed. For the three months ended September 30, 2011 testing services totaled $84,275, and there were no testing services for the three months ended September 30, 2012. Testing services totaled $234,512 for the nine months ended September 30, 2011, and there were no testing services for the nine months ended September 30, 2012.

Commission Agreement with Hitachi Chemical Co., Ltd.

On July 26, 2007, the Company entered into a collaboration agreement with Hitachi Chemical Co., Ltd. ("Hitachi"), a leading diagnostics manufacturer in Japan. Under the terms of this agreement, Hitachi uses the Company's proprietary and patented techniques to extract genetic information from FFPE tissue samples collected in Southeast Asia, Australia and New Zealand. As part of this collaboration agreement, the Company provides Hitachi with the technical information and assistance necessary to perform the testing services. Hitachi is responsible for expenses related to the cost of laboratory equipment and modification to the laboratory facilities, as well as the cost of reagents. The Southeast Asian countries covered under this agreement include Japan, North Korea, South Korea, Taiwan, Mongolia, Pakistan, Bangladesh, Sri Lanka, Nepal, Singapore, Malaysia, Indonesia, Brunei, Thailand, Myanmar, Laos, Cambodia, Vietnam and the Philippines (the "Territory").

The collaboration agreement had an initial term expiring on June 30, 2010, with an automatic renewal for one year at the end of the original period under the same terms and conditions. Pursuant to the agreement, Hitachi performs certain testing services and receives a percentage of the revenue collected from the Company's clients in the Territory, which totaled $106,260 and $291,728 for the three months ended September 30, 2011 and 2012, respectively and $481,951 and $526,057 for the nine months ended September 30, 2011 and 2012, respectively. Due to the closing of Hitachi's applicable facility in the Territory, the Company and Hitachi have agreed to terminate this agreement effective September 30, 2012 pending delivery of certain outstanding items by Hitachi.

XML

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Lease Payments under Noncancelable Operating Leases

Years Ending December 31,	Unaudited
2012	$	161,780
2013		309,560
Total	$	471,340

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies [Abstract]

Basis of Consolidation

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Response Genetics, Ltd., a Scottish corporation, which was incorporated in November 2006. All significant intercompany transactions and balances have been eliminated in consolidation.

Reclassification

Reclassification

Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company's financial condition as of December 31, 2011 nor statement of operations for the period ended September 30, 2011.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity date of three months or less from the date of purchase to be cash equivalents. The carrying value of cash equivalents approximates fair value due to the short-term nature and liquidity of these instruments. The Company's cash equivalents are comprised of cash on hand, deposits in banks and money market investments.

Accounts Receivable

Accounts Receivable

Pharmaceutical Accounts Receivable

The Company invoices its clients as specimens are processed and any other contractual obligations are met. The Company's contracts with clients typically require payment within 45 days of the date of invoice. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its clients to make required payments. The Company specifically analyzes accounts receivable and historical bad debts, client credit, current economic trends and changes in client payment trends when evaluating the adequacy of the allowance for doubtful accounts. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered. To date, the Company's pharmaceutical customers have primarily been large pharmaceutical companies. As a result, bad debts from pharmaceutical accounts receivable to date have been minimal. Pharmaceutical company accounts receivable as of December 31, 2011 and September 30, 2012 were $1,701,837 and $1,423,646, respectively. There were no allowances for doubtful accounts recorded against these pharmaceutical accounts receivable at December 31, 2011 and September 30, 2012.

ResponseDX^® Accounts Receivable

ResponseDX^® accounts receivable are recorded from two primary payors: Medicare and third party and private payors ("Private Payors"). ResponseDX^® accounts receivable are recorded at established billing rates less an estimated billing adjustment, based on reporting models utilizing historical cash collection percentages and updated for current effective reimbursement factors. Management performs ongoing valuations of accounts receivable balances based on management's evaluation of historical collection experience and industry trends in order to record an allowance for doubtful accounts. Based on the historical experience for the Company's Medicare and Private Payor accounts, management has determined that related accounts receivable associated with billings over one year are unlikely to be collected. Any outstanding receivable balance that is over one year old is written off. The Company's bad debt expense for the three months ended September 30, 2011 and 2012, was $160,952 and $589,917, respectively, and $460,883 and $897,128 for the nine months ended September 30, 2011 and 2012.

ResponseDX^® accounts receivable as of December 31, 2011 and September 30, 2012, consisted of the following:

	December 31, 2011			September 30, 2012
				(Unaudited)
Net Medicare receivable	$	506,308		$	774,237
Net Private Payor receivable		2,634,838			3,050,494
Other		42,826			-
		3,183,972			3,824,731
Allowance for doubtful accounts		(838,750	)		(864,419	)
Total	$	2,345,222		$	2,960,312

Property and Equipment

Property and Equipment

Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the double declining balance and straight-line methods over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows:

Laboratory equipment	5 to 7 years
Furniture and Equipment	5 to 7 years
Leasehold Improvements	Shorter of the useful life (5 to 7 years) or the lease term

Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. The Company has capitalized costs related to the development of database software (see Note 3). The portion of this database placed into service is amortized in accordance with ASC 350-40, Internal-Use Software. The amortization period is three years using the straight-line method.

Revenue Recognition

Revenue Recognition

Pharmaceutical Revenue

Revenues that are derived from testing services provided to pharmaceutical companies are recognized on a contract specific basis pursuant to the terms of the related agreements. Revenue is recognized in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.

Revenues are recorded on an accrual basis as the contractual obligations are completed and as a set of assays is processed through the Company's laboratory under a specified contractual protocol and are recorded on the date the tests are resulted. Certain contracts have minimum assay requirements that, if not met, result in payments that are due upon the completion of the designated period. In these cases, revenues are recognized when the end of the specified contract period is reached.

On occasion, the Company may enter into a contract that requires the client to provide an advance payment for specimens that will be processed at a later date. In these cases, the Company records this advance as deferred revenue and recognizes the revenue as the specimens are processed or at the end of the contract period, as appropriate.

ResponseDX^® Revenue

Revenues that are derived from ResponseDX^® testing services are recognized in accordance with ASC 605, Revenue Recognition , which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered. (3) the price is fixed or determinable; and (4) collectability is reasonably assured. We record revenues when our tests have confirmed results which is evidence that the services have been performed.

Revenues are recorded on an accrual basis as the contractual obligations are completed and as a set of assays is processed through our laboratory under a specified contractual protocol.

ResponseDX^® Private Payor and Medicare revenues are recorded on an accrual basis at established billing rates less an estimated billing adjustment, based on reporting models utilizing historical cash collection percentages and updated for current effective reimbursement factors. The Company's Medicare provider number allows it to invoice and collect from Medicare. The Company's invoicing to Medicare is primarily based on amounts allowed by Medicare for the service provided as defined by Common Procedural Terminology ("CPT").

The following details ResponseDX^® revenue for the three and nine months ended September 30, 2011 and 2012:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	(Unaudited)				(Unaudited)
	2011		2012		2011		2012
Net Medicare revenue	$	1,572,807	$	1,227,893	$	4,029,675	$	3,995,200
Private Payor revenue		1,765,753		1,795,723		5,389,199		4,814,403
Other		2,076		-		6,873		-
Net ResponseDX® revenue	$	3,340,636	$	3,023,616	$	9,425,747	$	8,809,603

Cost-Containment Measures

Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of health care services, which include diagnostic test providers such as the Company, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.

Regulatory Matters

A portion of the Company's revenues are derived from Medicare reimbursement. Laws and regulations governing Medicare programs are complex and subject to interpretation, and the Company may be adversely affected by future governmental investigations, lawsuits or private actions which include mandatory damages, fines, penalties, criminal charges, loss of suspension of licenses and/or suspension or exclusion from Medicare and certain other governmental programs. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing.

Medicare reimbursement rates are subject to regulatory changes and government funding restrictions. The Company is aware of public comments and associated commentary related to future rate changes that may occur in early 2013. Significant changes to the reimbursement rates could have a material adverse effect on the Company's operations.

Cost of Revenue

Cost of Revenue

Cost of revenue represents the cost of materials, direct labor, royalties, costs associated with processing tissue specimens including pathological review, staining, microdissection, paraffin extraction, reverse transcription polymerase chain reaction, ALK Break Apart fluorescence in situ hybridization (FISH), quality control analyses, license fees and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.

License Fees

License Fees

The Company has licensed technology for the extraction of mRNA from formalin-fixed, paraffin-embedded tumor specimens from the University of Southern California ("USC"). Under the terms of the license agreement, the Company is required to pay royalties to USC based on the revenue generated by use of this technology. The Company maintains a non-exclusive license to use certain patents related to the polymerase chain reaction ("PCR") of Roche Molecular Systems, Inc. ("Roche"). The Company pays Roche a royalty fee based on revenue that the Company generates through use of this technology. The Company accrues for such royalties at the time revenue is recognized. Such royalties are included in cost of revenues in the accompanying statements of operations.

Research and Development

Research and Development

The Company expenses costs associated with research and development activities as incurred. Research and development costs are expensed as incurred in relation to direct costs that can be identified and classified as research and development costs. Certain costs such as lab supplies and reagents that cannot be specifically identified are allocated based on the number of samples processed in total by the lab and R&D departments in total. Research and development costs include employee costs (salaries, payroll taxes, benefits, and travel), equipment depreciation and warranties and maintenance, laboratory supplies, primers and probes, reagents, patent costs and occupancy costs.

Line of Credit

Line of Credit

On July 14, 2011, the Company entered into a line of credit agreement with Silicon Valley Bank (the "Bank"). The agreement has been amended most recently on September 28, 2012. The line of credit is collateralized by the Company's pharmaceutical and Medicare receivables. The amended maximum amount that can be borrowed from the credit line is $2,000,000. The amount the Company can draw from the loan is equal to the calculated borrowing base, which is 80% of the Company's pharmaceutical accounts receivable that have not aged greater than 90 days. As of September 30, 2012, the amount available for the borrowing base is fixed at $1,500,000 until November 30, 2012. As part of the line of credit the Bank will issue letters of credit up to a maximum amount of $500,000. Any issued letters of credit reduce the amount available to borrow under the line of credit on a dollar for dollar basis. The interest fees associated with this line of credit are set at the prime rate plus 1%. For the period ended September 30, 2012, the rate being charged to the Company was 5%. As needed from time to time, the Company may draw on this line for use for general corporate purposes. As of December 31, 2011 and September 30, 2012, the Company has drawn $1,000,000 against the line of credit and no letters of credit were outstanding. The line of credit is subject to various financial covenants and, as of September 30, 2012, the Company was not in compliance with certain covenants. The September 28, 2012 amendment provided forbearance for the failure to comply with these certain covenants through November 30, 2012, and the amendment modified the covenants to include a requirement that the Company maintain account balances at the Bank totaling a minimum of $4,000,000 during the forbearance period. Management intends to utilize the forbearance period to restructure the line of credit agreement and any related covenant compliance issues. As of December 31, 2011, and September 30, 2012, the line of credit was classified as a current liability of the Company on the accompanying balance sheet. However, there can be no assurance that the Company will be able to restructure the line of credit agreement during the forbearance period on terms acceptable to the Company, or at all, nor can there be any assurance that the Company will be able to resolve all such covenant compliance issues during the forbearance period.

From time to time the Company's borrowing base under its Bank line of credit may decrease to a level where the Company is in an over-advance position. This occurred on one occasion during the second quarter of 2012 based on the May 2012 borrowing base, as a result of which the Company was required to repay $298,000 to the Bank. The Company drew down the same amount one week later once the June 2012 borrowing base was determined to be sufficiently higher than the May 2012 borrowing base, thereby giving the Company the capacity to borrow such additional amount.

Income Taxes

Income Taxes

Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

ASC 740, Income Taxes , clarifies the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of December 31, 2011 and September 30, 2012, the Company does not have a liability for unrecognized tax benefits. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related tax liability in the balance sheet. For the period ended September 30, 2012 there were no interest or penalties recorded on the Consolidated Statement of Operations.

Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Stock Compensation, Share-Based Payment. Stock-based compensation expense for all stock-based compensation awards granted is based on the grant-date fair value estimated in accordance with the provisions of ASC 718. The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting period. As further described in Note 7, certain awards granted to Thomas Bologna, the Company's Chairman and Chief Executive Officer, were recognized based on an accelerated vesting basis triggered by market conditions rather than a straight-line basis.

The Company accounts for equity instruments issued to non-employees in accordance with ASC 505, Equity . Under ASC 505, stock option awards issued to non-employees are measured at fair value using the Black-Scholes option-pricing model and recognized pursuant to a performance model.

Management Estimates

Management Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates in these consolidated financial statements have been made for revenue, allowances for contractual and doubtful accounts, impairment of long-lived assets, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.

Long-lived Assets

Long-lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates potential impairment by comparing the carrying amount of the asset with the estimated undiscounted future cash flows associated with the use of the asset and its eventual disposition. Should the review indicate that the assets cost is not recoverable, the carrying value of the asset would be reduced to its estimated fair value, which is measured by future discounted cash flows.

Foreign Currency Translation

Foreign Currency Translation

The financial position and results of operations of the Company's foreign subsidiary are determined using local currency as the functional currency. Assets and liabilities of these operations are translated at the exchange rate in effect at each period-end. Statement of Operations amounts are translated at the average rate of exchange prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss in stockholders' equity (deficit).

Comprehensive Loss

Comprehensive Loss

The components of comprehensive loss are accumulated net loss and unrealized foreign currency translation adjustments for the three and nine months ended September 30, 2011 and 2012.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

For cash and cash equivalents, accounts receivable, accounts payable, capital lease obligations and the line of credit the carrying amount approximates fair market value. Cash equivalents consist of money market accounts, with fair values estimated based on quoted market prices. For additional information see Note 12.

Advertising Costs

Advertising Costs

The Company markets its services through its advertising activities in trade publications and on-line. Advertising costs are included in selling and marketing expenses on the statements of operations and are expensed as incurred. Advertising costs for the three months ended September 30, 2011 and 2012 were $16,985 and $655, respectively and $83,462 and $13,626 for the nine months ended September 30, 2011 and 2012, respectively.

Concentration of Credit Risk and Clients and Limited Suppliers

Concentration of Credit Risk and Clients and Limited Suppliers

Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All of the Company's non-interest bearing cash balances were fully insured at September 30, 2012 due to a temporary federal program in effect from December 31, 2011 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning on January 1, 2013, federal insurance coverage is scheduled to revert to $250,000 per depositor at each financial institution, and the Company's non-interest bearing cash balances may again exceed federally insured limits. There were no funds in interest-bearing accounts that exceeded the federally insured limits as of September 30, 2012. At September 30, 2012, $8,053 of cash was held outside of the United States and is uninsured.

Revenue sources that account for greater than 10 percent of total revenue are provided below.

	Three Months Ended September 30,										Nine Months Ended September 30,
	2011					2012					2011					2012
	(Unaudited)										(Unaudited)
	Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue
GlaxoSmithKline	$	356,594		7	%	$	777,571		14	%	$	2,878,860		16	%	$	1,000,147		8	%
GlaxoSmithKline Biologicals	$	1,109,112		22	%	$	886,945		16	%	$	4,186,385		24	%	$	1,619,372		12	%
Medicare, net of contractual allowances	$	1,572,807		31	%	$	1,227,893		23	%	$	4,029,676		23	%	$	3,995,200		30	%

Customers that account for greater than 10 percent of gross accounts receivable are provided below.

	As of December 31, 2011					As of September 30, 2012
	( Unaudited )					( Unaudited )
	Receivable Balance		Percent of Total Receivables			Receivable Balance		Percent of Total Receivables
GlaxoSmithKline	$	476,526		10	%	$	275,553		5	%
GlaxoSmithKline Biologicals	$	1,079,570		22	%	$	276,206		5	%
Medicare, net of contractual allowances	$	506,308		10	%	$	774,237		15	%

Many of the supplies and reagents used in the Company's testing process are procured from a limited number of suppliers. Any supply interruption or an increase in demand beyond the suppliers' capabilities could have an adverse impact on the Company's business. Management believes it could identify alternative sources, if necessary, but it is possible such sources may not be identified in sufficient time to avoid an adverse impact on the Company's business. Refer also to Note 6 for further discussion regarding these supply agreements. The Company purchases certain laboratory supplies and reagents primarily from two suppliers and purchases from these two companies accounted for approximately 76% and 71% of the Company's reagent purchases for the three months ended September 30, 2011 and 2012, respectively and approximately 75% and 70% for the nine months ended September 30, 2011 and 2012, respectively.

XML

Segment Information

9 Months Ended

Sep. 30, 2012

Segment Information [Abstract]

Segment Information

10. Segment Information

The Company operates in a single reporting segment, with an operating facility in the United States.

The following enterprise wide disclosure was prepared on a basis consistent with the preparation of the consolidated financial statements. The following tables contain certain financial information by geographic area:

	Three Months Ended September 30,				Nine Months Ended September 30,
Net Revenue:	2011		2012		2011		2012
	(Unaudited)				(Unaudited)
United States	$	3,833,037	$	3,890,842	$	12,740,800	$	10,310,236
Europe		1,109,112		893,060		4,186,385		1,672,387
Japan		158,500		619,635		803,600		1,237,565
	$	5,100,649	$	5,403,537	$	17,730,785	$	13,220,188

Long-lived assets:	December 31, 2011		September 30, 2012
			(Unaudited)
United States	$	1,112,102	$	1,490,572

XML

Common Stock Warrants

9 Months Ended

Sep. 30, 2012

Common Stock Warrants [Abstract]

Common Stock Warrants

8. Common Stock Warrants

The Company issues warrants to purchase common shares of the Company either as compensation for services or as additional incentive for investors who may purchase common stock. The value of warrants issued for compensation is accounted for as a non-cash expense to the Company at the fair value of the warrants issued.

In June 2007, in conjunction with the initial public offering, the Company issued 100,000 warrants to purchase 100,000 shares of its common stock at an exercise price of $7.70 to the underwriters as part of the initial public offering. There were no warrants granted during the three months ended September 30, 2011 and 2012. As of September 30, 2012, all of the warrants that were outstanding and exercisable had expired.

XML

Income Taxes

9 Months Ended

Sep. 30, 2012

Income Taxes [Abstract]

Income Taxes

9. Income Taxes

Deferred income taxes result from temporary differences between income tax and financial reporting computed at the effective income tax rate. The Company has established a valuation allowance against its net deferred tax asset due to the uncertainty surrounding the realization of such asset. Management periodically evaluates the recoverability of the deferred tax assets. At such time it is determined that it is more likely than not that deferred tax assets are realizable, the valuation allowance will be reduced.

The Company files U.S. federal, U.S. state, and foreign tax returns. The Company's major tax jurisdictions are U.S. federal and the State of California. The Company is subject to tax examinations for the open years from 2002 through 2011.

XML

Sale of Common Stock

9 Months Ended

Sep. 30, 2012

Sale of Common Stock [Abstract]

Sale of Common Stock

11. Sale of Common Stock

May 2011 Registered Offering of Common Stock

On May 6, 2011, the Company issued 1,175,512 shares of its common stock at a price of $1.99 per share in a registered direct public offering to certain institutional investors and received net proceeds of approximately $2.2 million from the sales, after deducting its estimated offering expenses. The securities issued with this financing were registered under the Securities Act of 1933, as amended. The shares were issued pursuant to a prospectus supplement dated May 4, 2011 and an accompanying prospectus dated January 6, 2011, pursuant to the Company's existing effective shelf registration statement on Form S-3 (File No. 333-171266), which was filed with the Securities and Exchange Commission on December 17, 2010 and declared effective by the SEC on January 6, 2011.

Common stock classified outside of stockholders' equity (deficit)

March 2010 Private Placement

On March 5, 2010, the Company entered into a purchase agreement with certain affiliates of and funds managed by Lansdowne Partners Limited Partnership ("Lansdowne"), Greenway Capital Partners and Paragon Associates for the private placement of 3,005,349 newly-issued shares of the Company's common stock at a per share price of $1.31. The closing of the sale of the shares occurred on March 5, 2010. In connection with the acquisition of the shares, the purchasers were granted certain preemptive rights permitting them to maintain their percentage ownership interests in connection with future issuances of the Company's capital stock, subject to various exceptions and limitations. Lansdowne participated in the private placement by electing to exercise the preemptive rights granted to it pursuant to the purchase agreement by and between the Company and Lansdowne, dated July 22, 2009. Net proceeds received from this financing were approximately $3,879,403.

In connection with the private placement, the Company also entered into a registration rights agreement, dated March 5, 2010, with the purchasers pursuant to which it agreed to file, within 45 days of the closing of the private placement, a registration statement with the SEC to register the shares for resale, which registration statement was required to become effective within 120 days following the closing. The Company also granted certain "piggyback" registration rights to the purchasers which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more shareholders until the earlier of the sale of all of the shares or the shares becoming eligible for sale under Rule 144(b)(1) without restriction.

Pursuant to the registration rights agreement, dated March 5, 2010, the Company filed a registration statement with the SEC to register the 3,005,349 shares sold to Lansdowne, Greenway and Paragon for resale, which became effective on May 19, 2010 and which registration statement remained effective as of September 30, 2012.

Under the registration rights agreements with the purchasers, the Company is obligated to use commercially reasonable efforts to (i) cause the registration statement described above to remain continuously effective and (ii) to maintain the listing of Company's common stock on NASDAQ or other exchanges, as defined, for a period that will terminate on the earlier of March 5, 2013 or the date on which the purchasers have sold all shares of common stock. The Company is also required to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In the event the Company fails to satisfy its obligations under the registration rights agreements, the Company would be in breach of said agreements, in which event, the purchases would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. These registration rights agreements do not provide an explicitly stated or defined penalty due upon a breach. Because (i) the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements and (ii) complying with all filing requirements under the Exchange Act as described above is not solely within the Company's control, the Company is required to present the investment of approximately $3,879,403 in the Company's common stock as common stock outside of stockholders' equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities .

On January 18, 2012, the Company removed the restrictions on 3,658,676 shares purchased by Lansdowne and reclassified the shares to common stock from common stock classified outside of equity(deficit).

February 2012 Private Placement

On February 2, 2012, the Company entered into purchase agreements with various investors (collectively, the "February Investors") for the private placement of an aggregate of 5,257,267 newly-issued shares of the Company's common stock (the "February Shares") at a purchase price of $1.50 per share (the "February 2012 Private Placement"). Net cash proceeds raised in the February 2012 Private Placement were approximately $7,822,000. The February Investors participating in the February 2012 Private Placement were various institutions and all officers and directors of the Company. The final closing of the February 2012 Private Placement (the "February Closing") occurred on February 2, 2012.

In connection with the February 2012 Private Placement, the Company also entered into registration rights agreements, each dated February 2, 2012, with the February Investors pursuant to which the Company agreed to file, within 90 days of the February Closing, a registration statement with the SEC to register the February Shares for resale, which registration statement is required to become effective within 180 days following the February Closing. The Company also granted the February Investors certain "piggyback" registration rights, which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more shareholders until the earlier of the sale of all of the February Shares or the February Shares becoming eligible for sale under Rule 144(b)(1) without restriction.

Pursuant to the registration rights agreements dated February 2, 2012, the Company filed a registration statement with the SEC on April 30, 2012, to register the February Shares for resale. This registration statement became effective on May 17, 2012 and remained effective as of September 30, 2012.

Under the registration rights agreements with the February Investors, the Company is obligated to use commercially reasonable efforts to (i) cause the registration statements described above to remain continuously effective and (ii) to maintain the listing of Company's common stock on NASDAQ or other exchanges, as defined, for a period that will terminate on the earlier of February 2013, or the date on which the February Investors have sold all shares of common stock. The Company is also required to file with the SEC in a timely manner all reports and other documents required of the Company required of the Company under the Exchange Act. In the event the Company fails to satisfy its obligations under the registration rights agreements, the Company would be in breach of said agreements, in which event, the February Investors would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. These registration rights agreements do not provide an explicitly stated or defined penalty due upon a breach. Because (i) the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements and (ii) complying with all filing requirements under the Exchange Act as described above is not solely within the Company's control, the Company is required to present the investment of approximately $7,884,400 in the Company's common stock as common stock outside of stockholders' equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities.

September 2012 Private Placement

On September 13, 2012, the Company entered into a purchase agreement (the "Purchase Agreement") with Glaxo Group Limited, an affiliate of GSK (the "GSK Investor") and two existing investors, Swiftcurrent Partners, L.P. and Swiftcurrent Offshore, Ltd. (collectively with the GSK Investor, the "September Investors") for the private placement of an aggregate of 8,000,000 newly-issued shares of the Company's common stock (the "September Shares") at a purchase price of $1.10 per share (the "September 2012 Private Placement"). The Company raised gross cash proceeds of $8,800,000 in the September 2012 Private Placement which closed (the "Closing") on September 13, 2012.

Pursuant to the Purchase Agreement, for so long as the GSK Investor or its affiliates own at least 50% of the September Shares it purchased pursuant to the Purchase Agreement, the GSK Investor has the right to designate one non-voting board observer (the "Board Observer"). The Board Observer, if appointed, has the right to attend all meetings of the Board of Directors of the Company and to receive all board meeting materials, subject to certain restrictions set forth in the Purchase Agreement. As of the date hereof, the GSK Investor has not exercised its right to designate the Board Observer.

In connection with the September 2012 Private Placement, the Company also entered into a registration rights agreement, dated September 13, 2012 (the "September Registration Rights Agreement"), with the September Investors pursuant to which the Company agreed to file, within 45 days of the Closing, a registration statement with the SEC to register the September Shares for resale, which registration statement is required to become effective within 180 days following the Closing. The Company also granted the September Investors certain "piggyback" registration rights, which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more stockholders until the earlier of the sale of all of the September Shares or the September Shares becoming eligible for sale under Rule 144(b)(1) without restriction.

Under the September Registration Rights Agreement, the Company is obligated to use commercially reasonable efforts to cause a registration statement to become effective and to remain continuously effective and to maintain the listing of the covered common stock on NASDAQ or other exchanges, as defined, for a period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration Statement as amended from time to time, have been sold, (ii) the date on which there are no longer any Registrable Securities outstanding or (iii) three years from the date of filing of such Registration Statement (the " Effectiveness Period ") and advise each September Investor in writing when the Effectiveness Period has expired. "Registrable Securities" means (i) the September Shares and (ii) shares of capital stock or any other securities issued or issuable with respect to or in exchange for the September Shares; provided, that, a security shall cease to be a Registrable Security with respect to a September Investor upon (A) sale by such September Investor pursuant to a registration statement or Rule 144 under the 1933 Act, or (B) such security becoming eligible for sale by such September Investor without restriction pursuant to Rule 144(b)(1). In the event the Company fails to satisfy its obligations under the September Registration Rights Agreement, the Company would be in breach of such agreement, in which event, the September Investors would be entitled to pursue all rights and remedies at law or equity including an injunction or other equitable relief. The September Registration Rights Agreement does not provide an explicitly stated or defined penalty due upon a breach. Because the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements, the Company is required to present the investment of approximately $8,800,000 in the Company's common stock as common stock outside of stockholders' equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities.

Pursuant to the September Registration Rights Agreement, the Company filed a registration statement with the SEC on October 26, 2012, to register the September Shares for resale. This registration statement became effective on November 13, 2012.

As of December 31, 2011 and September 30, 2012, a total of $7,854,682 and $19,575,724 of common stock was classified outside of stockholders' equity (deficit), respectively.

XML

Property and Equipment and Intangible Assets (Schedule of Property and Equipment and Intangible Assets) (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,168,509	$ 3,856,032
Less: Accumulated depreciation	(3,141,947)	(2,810,745)
Total property and equipment, net	1,026,562	1,045,287
Intangible assets	554,243	139,966
Less: Accumulated amortization	(90,233)	(73,151)
Total intangible assets, net	464,010	66,815
Purchased Software [Member]
Property, Plant and Equipment [Line Items]
Intangible assets	445,881	91,505
Internally Developed Software [Member]
Property, Plant and Equipment [Line Items]
Intangible assets	108,362	48,461
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,208,449	3,036,274
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	660,626	624,859
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 299,434	$ 194,899

XML

Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Segment Reporting Information [Line Items]
Revenue	$ 5,403,537	$ 5,100,649	$ 13,220,188	$ 17,730,785
United States [Member]
Segment Reporting Information [Line Items]
Revenue	3,890,842	3,833,037	10,310,236	12,740,800
Long-lived assets	1,490,572		1,490,572		1,112,102
Europe [Member]
Segment Reporting Information [Line Items]
Revenue	893,060	1,109,112	1,672,387	4,186,385
Japan [Member]
Segment Reporting Information [Line Items]
Revenue	$ 619,635	$ 158,500	$ 1,237,565	$ 803,600

XML

Property and Equipment and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2012

Property and Equipment and Intangible Assets [Abstract]

Schedule of Property and Equipment

	December 31, 2011			September 30, 2012
				(Unaudited)
Laboratory equipment	$	3,036,274		$	3,208,449
Office furniture and equipment		624,859			660,626
Leasehold improvements		194,899			299,434
		3,856,032			4,168,509
Less: Accumulated depreciation		(2,810,745	)		(3,141,947	)
Total property and equipment, net	$	1,045,287		$	1,026,562
Purchased software	$	91,505		$	445,881
Internally developed software		48,461			108,362
		139,966			554,243
Less: Accumulated amortization		(73,151	)		(90,233	)
Total intangible assets, net	$	66,815		$	464,010

Schedule of Capital Leased Assets

	(Unaudited)
Equipment purchased under capital leases	$	451,234
Less: Accumulated amortization		(170,392	)
Equipment purchased under capital leases, net	$	280,842

Schedule of Future Minimum Lease Payments Under Capital Leases

Years ending December 31,	(Unaudited)
2012	$	44,907
2013		175,548
2014		87,119
Total minimum lease payments		307,574
Less amount represented by interest		(26,732	)
Less current portion		(158,821	)
Capital lease obligation, net of current portion	$	122,021

XML

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2012

Fair Value Measurements [Abstract]

Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis

	Fair Value Measurement as of September 30, 2012 (Unaudited)
	Total		Level 1		Level 2		Level 3
Description	$		$		$		$
Money market accounts (1)		10,000		10,000		-		-

(1) Included in cash and cash equivalents on the accompanying consolidated balance sheet.

XML

Common Stock Warrants (Details)	1 Months Ended
	Jun. 30, 2007
Common Stock Warrants [Abstract]
Warrants issued in conjunction with the initial public offering	100,000
Warrants issued to purchase shares of common stock	100,000
Exercise price of the warrants	7.7

XML

Commitments and Contingencies (Schedule of Future Minimum Lease Payments under Noncancelable Operating Leases) (Details) (USD $)	Sep. 30, 2012
Commitments and Contingencies [Abstract]
2012	$ 161,780
2013	309,560
Total	$ 471,340

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (7,269,739)	$ (1,759,775)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	348,284	262,591
Share-based compensation	683,897	703,771
Bad debt expense	897,182	460,883
Loss on sale of property and equipment		7,728
Asset impairment		157,241
Changes in operating assets and liabilities:
Accounts receivable	(1,211,800)	(823,671)
Prepaid expenses and other current assets	520,632	148,244
Accounts payable	(144,285)	(46,697)
Accrued expenses	(737,351)	(787,047)
Accrued royalties	(46,201)	(331,803)
Accrued payroll and related liabilities	(333,672)	(174,863)
Deferred revenue	803,481	(1,133,316)
Net cash used in operating activities	(6,489,572)	(3,316,714)
Cash flows from investing activities:
Purchases of property and equipment	(312,477)	(287,995)
Purchases and capitalization of software	(414,277)	(69,159)
Net cash used in investing activities	(726,754)	(357,154)
Cash flows from financing activities:
Net proceeds from issuance of common stock	16,464,965	2,179,535
Proceeds on exercise of stock options		5,411
Capital lease payments	(109,339)	(16,041)
Net cash provided by financing activities	16,355,626	2,168,905
Effect of foreign exchange rates on cash and cash equivalents	(394)	(83,102)
Net increase (decrease) in cash and cash equivalents	9,138,906	(1,588,065)
Cash and cash equivalents:
Beginning of period	1,700,295	4,120,074
End of period	10,839,201	2,532,009
Cash paid during the period for:
Interest	$ 66,556	$ 11,379

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies [Abstract]

Commitments and Contingencies

5. Commitments and Contingencies

Operating Leases

The Company leases 20,753 square feet of office and laboratory space in Los Angeles, California, under a noncancelable operating lease that will expire on June 30, 2013. The Company also leases 1,460 square feet of space in Frederick, Maryland, where administrative functions were performed until July 31, 2012. The Maryland lease expires on January 31, 2013. The Company moved the administrative functions performed out of this office primarily to its Los Angeles facilities and closed the Maryland office on July 31, 2012. The Company is working with the landlord of the Maryland office to find a replacement tenant for the space so that the Company can be released from its obligations under this lease.

Rent expense, which is classified in cost of revenue, general and administrative, and research and development expenses was $112,548 and $156,088 for the three months ended September 30, 2011 and 2012, respectively, and $371,553 and $508,456 for the nine months ended September 30, 2011 and 2012, respectively.

Future minimum lease payments by year and in the aggregate, under the Company's noncancelable operating leases, consist of the following at September 30, 2012:

Years Ending December 31,	Unaudited
2012	$	161,780
2013		309,560
Total	$	471,340

Guarantees

The Company enters into indemnification provisions under its agreements with other counterparties in its ordinary course of business, typically with business partners, clients and landlords. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company's activities. These indemnification provisions generally survive termination of the underlying agreement. The Company reviews its exposure under these agreements no less than annually, or more frequently when events indicate. The Company believes the estimated fair value of these agreements is minimal as, historically, no payments have been made by the Company under these indemnification obligations. Accordingly, the Company has no liabilities recorded for these agreements as of December 31, 2011 and September 30, 2012.

Legal Matters

The Company is, from time to time, involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. These matters are not expected to have a material adverse effect upon the Company's financial condition.

Employment Agreements

The Company has employment contracts with several individuals, which provide for annual base salaries and potential bonuses. These contracts contain certain change of control, termination and severance clauses that require the Company to make payments to certain of these employees if certain events occur as defined in their respective contracts.

XML

Organization, Operations and Basis of Accounting (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Organization, Operations and Basis of Accounting [Abstract]
Accumulated deficit	$ 56,789,324	$ 49,519,585

XML

Loss Per Share (Computation for Basic and Diluted Loss Per Share) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Numerator:
Net loss	$ (1,415,488)	$ (1,415,540)	$ (7,269,739)	$ (1,759,775)
Numerator for basic and diluted earnings per share	$ (1,415,488)	$ (1,415,540)	$ (7,269,739)	$ (1,759,775)
Denominator:
Denominator for basic and diluted earnings per share - weighted-average shares	26,362,842	19,537,232	24,709,185	18,979,010
Basic and diluted loss per share	$ (0.05)	$ (0.07)	$ (0.29)	$ (0.09)

XML

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies [Abstract]

Schedule of ResponseDX Accounts Receivable

	December 31, 2011			September 30, 2012
				(Unaudited)
Net Medicare receivable	$	506,308		$	774,237
Net Private Payor receivable		2,634,838			3,050,494
Other		42,826			-
		3,183,972			3,824,731
Allowance for doubtful accounts		(838,750	)		(864,419	)
Total	$	2,345,222		$	2,960,312

Schedule of Estimated Useful Lives of Property and Equipment

Laboratory equipment	5 to 7 years
Furniture and Equipment	5 to 7 years
Leasehold Improvements	Shorter of the useful life (5 to 7 years) or the lease term

Schedule of ResponseDX Revenue

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	(Unaudited)				(Unaudited)
	2011		2012		2011		2012
Net Medicare revenue	$	1,572,807	$	1,227,893	$	4,029,675	$	3,995,200
Private Payor revenue		1,765,753		1,795,723		5,389,199		4,814,403
Other		2,076		-		6,873		-
Net ResponseDX® revenue	$	3,340,636	$	3,023,616	$	9,425,747	$	8,809,603

Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue

	Three Months Ended September 30,										Nine Months Ended September 30,
	2011					2012					2011					2012
	(Unaudited)										(Unaudited)
	Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue
GlaxoSmithKline	$	356,594		7	%	$	777,571		14	%	$	2,878,860		16	%	$	1,000,147		8	%
GlaxoSmithKline Biologicals	$	1,109,112		22	%	$	886,945		16	%	$	4,186,385		24	%	$	1,619,372		12	%
Medicare, net of contractual allowances	$	1,572,807		31	%	$	1,227,893		23	%	$	4,029,676		23	%	$	3,995,200		30	%

Schedule of Customers that Account for Greater than 10 Percent of Accounts Receivable

	As of December 31, 2011					As of September 30, 2012
	( Unaudited )					( Unaudited )
	Receivable Balance		Percent of Total Receivables			Receivable Balance		Percent of Total Receivables
GlaxoSmithKline	$	476,526		10	%	$	275,553		5	%
GlaxoSmithKline Biologicals	$	1,079,570		22	%	$	276,206		5	%
Medicare, net of contractual allowances	$	506,308		10	%	$	774,237		15	%